Regeneron Pharmaceuticals, Inc.  
Clinical Study Protocol  
RANDOMIZED, CONTROLL ED, MULTI -CENTER  STUDY TO ASSESS 
THE EFFICACY, SAFETY , AND TOLERABILITY O F INTRAVITREAL 
AFLIBERCEPT COMPARED  TO LASER PHOTOCOAGU LATION IN 
PATIENTS WITH RETINO PATHY OF PREMATURITY  
Compound : Intravitreal Aflibercept Injection  
Clinical Phase:  3 
Protocol Number:  VGFTe -ROP -1920  
Protocol Version:  VGFTe -ROP-1920 Amendment 1  
Amendment 1 Date of Issue:  See appended electronic signature [CONTACT_564607]:  27 Jun 2019  
Medical /Study Director:  
Regeneron Pharmaceuticals, Inc.  
[ADDRESS_1106405]  
Tarrytown, NY [ZIP_CODE]  
VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00Study ID: [REMOVED]
IND Number:  [ADDRESS_1106406] Number: 
 2019-001764-29 

Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
Regeneron Pharmaceuticals, Inc.  Page 2 of 66 
 CONFIDENTIAL  AMENDMENT HISTORY  
Amendment 1 
The following table outlines the changes made to the protocol and the affected sections:  
Change and Rationale for Change  Section Changed  
Updated statistical sections to describe the Per Protocol 
Set (PPS)  analysis , which is required for noninferiority 
studies.  Removed reference to p ooled analys es (with the 
Bayer sister study ) as this is no longer planned . Clinical Study Protocol Synopsis : Statistical Plan  
Section  11.3.1  Full Analysis Set  
Section  11.3.2  Per Protocol Set (new section)  
Section  [IP_ADDRESS]  Primary Efficacy Analysis  
Clarified that collection of demographic and baseline data 
includes relevant maternal history . Section  5.[ADDRESS_1106407] will be performed once 
only, at any time prior to discharge from the neonatal 
intensive care unit  (NICU) . Table  1 Schedule of Events (moved location of 
footnote  #4) 
Section  9.2.1  Procedures Performed  Only at the 
Screening/Baseline Visit  
Clarified that a second  central nervous system imaging 
will be carried out prior to discharge from the NICU.  Table  1 Schedule of Events (moved location of 
footnote  #5) 
Section  9.2.1  Procedures Performed  Only at the 
Screening/Baseline Visit  
Removed description o f volumes for blood sampling , as 
this information is referenced in other study document(s) . Section  9.1.1  Footnotes for the Schedule of Events Table 
(#13 and #14)  
Section  9.2.[ADDRESS_1106408] /Ethics Committee, and Investigators  
Added brief description of the RAINBOW study (in 
retinopathy of prematurity ) for clarity . Section  11.1 Statistical Hypothesis  
Administrative Changes  Section  1 Introduction  
Section  3.3.1  Known and Expected Benefits  
Section  3.3.2  Potent ial Risks and Mitigation Measures  
Section  5.2 Efficacy Variables  
Section  [IP_ADDRESS]  Ophthalmic Examinations  
Section  9.2.4  Treatment of Overdose  
Section  11.6 Additional Statistical Data Handling 
Conventions  
Minor editorial changes  Throughout  
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106409]  Aspartate aminotransferase  
BAER  Brainstem auditory evoked response  
BP Blood pressure  
BUN  Blood urea nitrogen  
CONSORT  Consolidated Standards of Reporting Trials  
CPK  Creatine phosphokinase  
CRF  Case report form (electronic or paper)  
CRO  Contract research organization  
DMC  Data monitoring committee  
DOB  Date of birth  
DWFI  Digital wide-field imaging/images (retina or fundus)  
EC Ethics Committee  
EDC  Electronic data capture  
EOS  End of study  
FA Fluorescein angiography  
FAS Full analysis set  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HDL  High -density lipoprotein  
ICF Informed consent form  
ICH International Council for Harmonisation  
IOP Intraocular pressure  
IRB Institutional Review Board  
IVRS  Interactive Voice Response System  
IVT Intravitreal  
IWRS  Interactive Web Response System  
LDH  Lactate dehydrogenase  
LDL  Low-density lipoprotein  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 4 of 66 
CONFIDENTIAL   
NAb  Neutralizing antibody  
PCSV  Potentially clinically significant value  
PD Pharmacodynamic  
PK Pharmacokinetic  
PPS Per protocol set  
RBC  Red blood cell  
RC Reading center  
Regeneron  Regeneron Pharmaceuticals, Inc.  
ROP  Retinopathy of prematurity  
SAE  Serious adverse event  
SAF Safety analysis set  
SAP Statistical analysis plan  
SAS Statistical Analysis System  
SC Subcutaneous  
SOC  System organ class  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
TEAE  Treatment -emergent adverse event  
US [LOCATION_002]  
VEGF  Vascular endothelial growth factor  
VEGF -A Vascular endothelial growth factor -A 
VEGFR1  Vascular endothelial growth factor receptor 1  
VEGFR2  Vascular endothelial growth factor receptor 2  
WBC  White blood cell  
 
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106410] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .................. 3 
CLINICAL STUDY PROTO COL SYNOPSIS ................................ ................................ ............. 11 
1. INTRODUCTION  ................................ ................................ ................................ ......16 
2. STUDY OBJECTIVES  ................................ ................................ .............................. 17 
2.1. Primary Objective  ................................ ................................ ................................ .......17 
2.2. Secon dary Objectives  ................................ ................................ ................................ .17 
2.3. Exploratory Objectives  ................................ ................................ ............................... 17 
3. HYPOTHESIS AND RATIO NALE  ................................ ................................ .......... 18 
3.1. Hypothesis  ................................ ................................ ................................ .................. 18 
3.2. Rationale  ................................ ................................ ................................ ..................... 18 
3.2.1.  Rationale for Study Design  ................................ ................................ ......................... 18 
3.2.2.  Rationale for Dose Selection  ................................ ................................ ...................... 18 
3.3. Risk-Benefit  ................................ ................................ ................................ ................ 18 
3.3.1.  Known and Expected Benefits  ................................ ................................ .................... 19 
3.3.2.  Potential Risks and Mitigation Measures  ................................ ................................ ...20 
[IP_ADDRESS].  Ocular Risks  ................................ ................................ ................................ ................ 20 
[IP_ADDRESS].  Hypersensitivity/Immunogenicity  ................................ ................................ .............. 20 
[IP_ADDRESS].  Acute Systemic Effects  ................................ ................................ ............................... 20 
4. ENDPOINTS  ................................ ................................ ................................ .............. 21 
4.1. Primary and Sec ondary Endpoints ................................ ................................ .............. 21 
4.1.1.  Primary Endpoint  ................................ ................................ ................................ ........ 21 
4.1.2.  Secondary Endpoints  ................................ ................................ ................................ ..21 
4.1.3.  Exploratory Endpoints  ................................ ................................ ................................ 21 
5. STUDY VARIABLES ................................ ................................ ................................ 22 
5.1. Demographic and Baseline Characteristics  ................................ ................................ 22 
5.2. Efficacy Variables  ................................ ................................ ................................ ......22 
5.3. Safety Variables  ................................ ................................ ................................ .......... 23 
5.4. Pharmacokinetic Variables  ................................ ................................ ......................... 23 
5.5. Immunogenicity Variables  ................................ ................................ .......................... 23 
5.6. Biomarker Variables  ................................ ................................ ................................ ...23 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106411]-study Treatments  ................................ ................................ ................................ 35 
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  ................................ ......35 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 7 of 66 
CONFIDENTIAL  9.1. Schedule of Events  ................................ ................................ ................................ .....35 
9.1.1.  Footnotes for the Schedule of Events Table  ................................ ............................... 38 
9.1.2.  Early Termination Visit  ................................ ................................ .............................. 39 
9.1.3. Unscheduled Visits  ................................ ................................ ................................ .....39 
9.2. Study Procedures  ................................ ................................ ................................ ........ 40 
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  ................................ .....40 
9.2.2.  Efficacy Procedures  ................................ ................................ ................................ ....40 
[IP_ADDRESS].  Other Ocular Assessments  ................................ ................................ .......................... 40 
9.2.3.  Safety Procedures  ................................ ................................ ................................ .......41 
[IP_ADDRESS].  Ophthalmic Examinations  ................................ ................................ .......................... 41 
[IP_ADDRESS].  Physical Examination  ................................ ................................ ................................ .41 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. 41 
[IP_ADDRESS].  Hearing Test  ................................ ................................ ................................ ................ 41 
[IP_ADDRESS].  Laboratory Testing  ................................ ................................ ................................ ......[ADDRESS_1106412] /Ethics Committee, 
and Investigators  ................................ ................................ ................................ ......... 49 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 8 of 66 
CONFIDENTIAL  11. STATISTICAL PLAN ................................ ................................ ................................ 50 
11.1.  Statistical Hypothesis  ................................ ................................ ................................ ..50 
11.2.  Justification of Sample Size ................................ ................................ ........................ 50 
11.3.  Analysis Sets  ................................ ................................ ................................ ............... 51 
11.3.1.  Full Analysis Set  ................................ ................................ ................................ ......... 51 
11.3.2.  Per Protocol Set  ................................ ................................ ................................ .......... 51 
11.3.3.  Safety Analysis Set  ................................ ................................ ................................ .....51 
11.3.4 . Pharmacokinetic Analysis Set  ................................ ................................ .................... 51 
11.3.5.  Immunogenicity Analysis Set  ................................ ................................ ..................... 51 
11.4.  Statistical Methods  ................................ ................................ ................................ ......51 
11.4.1.  Patient Disposition  ................................ ................................ ................................ ......51 
11.4.2.  Demography and Baseline Characteristics  ................................ ................................ .52 
11.4.3.  Efficacy Analyses  ................................ ................................ ................................ .......52 
[IP_ADDRESS].  Primary Efficacy Analysis  ................................ ................................ .......................... 52 
[IP_ADDRESS].  Secondary and Exploratory Efficacy Analyses  ................................ .......................... 52 
11.4.4.  Control of Multiplicity  ................................ ................................ ................................ 52 
11.4.5.  Safety Analysis  ................................ ................................ ................................ ........... 53 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 53 
[IP_ADDRESS] . Ocular Safety  ................................ ................................ ................................ .............. 53 
[IP_ADDRESS].  Other Safety  ................................ ................................ ................................ ................ 54 
[IP_ADDRESS].  Treatment Exposure  ................................ ................................ ................................ ....54 
[IP_ADDRESS].  Treatment Compliance  ................................ ................................ ................................ 54 
11.4.6.  Pharmacokinetics  ................................ ................................ ................................ ........ 54 
[IP_ADDRESS].  Analysis of Drug Concentration Data  ................................ ................................ ......... 54 
[IP_ADDRESS].  Pharmacokinetics and Pharmacokinetics/Pharmacodynamics Analyses  .................... 54 
11.4.7.  Analysis of Immunogenicity Data  ................................ ................................ .............. 54 
11.4.8.  Analysis of Biomarker Data  ................................ ................................ ....................... 55 
11.5.  Interim Analysis  ................................ ................................ ................................ .......... 55 
11.6.  Additional Statistical Data Handling Conventions  ................................ ..................... 55 
11.7.  Statistical Considerations Surrounding the Premature Termination of a Study  ......... 56 
12. QUALITY CONTROL AND QUALITY ASSURANCE  ................................ ......... 56 
12.1.  Data Management and Electronic Systems  ................................ ................................ 56 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 9 of 66 
CONFIDENTIAL  12.1.1.  Data Management  ................................ ................................ ................................ .......56 
12.1.2.  Electronic Systems  ................................ ................................ ................................ ......56 
12.2.  Study Monitoring  ................................ ................................ ................................ ........ 57 
12.2.1.  Monitoring of Study Sites  ................................ ................................ ........................... 57 
12.2.2.  Source Document Requirements  ................................ ................................ ................ 57 
12.2.3.  Case Report Form Requirements  ................................ ................................ ................ 57 
12.3.  Audits and Inspections  ................................ ................................ ................................ 57 
12.4. Study Documentation  ................................ ................................ ................................ .58 
12.4.1.  Certification of Accuracy of Data  ................................ ................................ ............... 58 
12.4.2.  Retention of Records  ................................ ................................ ................................ ..58 
13. ETHICAL AND REGULATO RY CONSIDERATIONS  ................................ .......... 58 
13.1.  Good Clinical Practice Statement  ................................ ................................ ............... 58 
13.2.  Informed Consent  ................................ ................................ ................................ .......59 
13.3.  Patients’ Confidentiality and Data Protection  ................................ ............................ [ADDRESS_1106413]/Ethics Committee  ................................ ........................... 60 
13.5.  Clinical Study Data Transparency  ................................ ................................ .............. 60 
14. PROTOCOL AMENDMENTS  ................................ ................................ .................. 60 
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSEOUT OF A 
SITE  ................................ ................................ ................................ ............................ 60 
15.1.  Premature Termination of the Study  ................................ ................................ ........... 60 
15.2.  Closeout of a Site  ................................ ................................ ................................ ........ 61 
16. CONF IDENTIALITY  ................................ ................................ ................................ 61 
17. FINANCING AND INSURA NCE  ................................ ................................ ............. 61 
18. PUBLICATION POLICY  ................................ ................................ .......................... 61 
19. REFERE NCES  ................................ ................................ ................................ ........... 62 
20. INVESTIGATOR’S AGREE MENT  ................................ ................................ .......... 64 
SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS ................................ ..................... 66 
 
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106414] OF TABLES  
Table  1: Schedule of Events  ................................ ................................ ................................ .....[ADDRESS_1106415] OF FIGURES  
Figure  1: Study Flow Diagram  ................................ ................................ ................................ ...25 
Figure  2: Aflibercept Treatment, Aflibercept Retreatment, and Rescue Treatment  .................. 27 
Figure  3: Laser Treatment, Laser Retreatment, and Rescue Treatment  ................................ .....[ADDRESS_1106416] OF APPENDICES  
APPENDIX  1. FLUORESCEIN ANGIOGRA PHY SUB -STUDY  ................................ ........... 65 
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 11 of 66 
CONFIDENTIAL  CLINICAL STUDY PROTO COL SYNOPSIS  
Title  Randomized, Controlled , Multi -Center  Study to Assess the Efficacy, Safety, 
and Tolerability of Intravitreal Aflibercept Compared to Laser 
Photocoagulation in Patients with Retinopathy of Prematurity  
Site Location(s)  
  
Principal Investigator  [INVESTIGATOR_101792] [ADDRESS_1106417] treating retinopathy of prematurity 
(ROP)  
Objective s The primary objective of the study is to assess the efficacy of aflibercept 
compared to laser in patients diagnosed with ROP.  
The secondary objectives of the study are:  
 To assess the need for a second treatment modality  
 To assess the recurrence of ROP in the study  
 To assess the safety and tolerability of aflibercept  
The exploratory objectives of the study are:  
 To further characterize the anatomical effects of treatment 
with aflibercept in patients with ROP  
 To further investigate the study intervention (eg, mode -of-
action -related effects and/or safety) rele vant to this disease 
process  
 To assess the treatment burden of aflibercept and laser  
 To characterize the concentrations of free and bound 
aflibercept in plasma over time  
 To describe the potential immunogenicity of aflibercept  
Study Design  This is a phase  3, multicenter, randomized, 2 -arm, open -label clinical study 
to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept 
versus laser in patients with ROP.  The study consists of screening/baseline 
(1 or 2  visits), a treatment perio d (including potential retreatment and rescue 
treatment), and a final visit at week 52 of chronological age.  
The study also includes an optional fluorescein angiography (FA) sub -study, 
which includes optional FA at baseline, and mandatory FA at week [ADDRESS_1106418] udy in all centers in all participating countries.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 12 of 66 
CONFIDENTIAL  Population   
 Sample Size:  Approximately 112 patients are planned to be enrolled in a 3:1 ratio 
(approximately 84  in the aflibercept group and approximately 28 in the laser 
group).  
 Target Population:  The study population will consist of male and female preterm infants with 
treatment -naïve ROP Zone I Stage 1 plus, 2 plus, 3 non -plus or plus, or 
Zone  II Stage 2 plus or 3 plus or AP -ROP according to the International 
Classification for ROP.  
Treatment(s)   
 Aflibercept  
 Dose/Route/Schedule:  Patients randomized to aflibercept will receive a single IVT injection of 
aflibercept 0.4 mg/0.01 mL per eligible eye at baseline.  
Thereafter, if required, up to 2 additional IVT injections of aflibercept 
0.4 mg/0.01 mL  may be administered in each eye in case both the following 
retreatment criteria are met:  
 Presence of ROP requiring treatment AND  
 The interval since the last aflibercept IVT injection is ≥28  days 
Rescue treatment with laser may be performed if 1 of the following 
conditions is met:  
 Worsening of ROP compared to the examination immediately 
preceding the previous aflibercept  injection, during the 27 
days following the aflibercept injection  
 Presence of ROP requiring treatment after the patient already 
receive d a total of [ADDRESS_1106419] from the fovea.  Laser ablation should 
be as complete as possible.  It is recommended that fundus photographs 
(digital wide -field imaging  [DWFI ]) should be obtained right after 
administration of laser treatment to look for “skip” areas, and if found, laser 
should be adminis tered to those areas prior to the investigator deeming the 
laser treatment as “complete .” In case multiple sessions are necessary within 
1 week from baseline, they will be counted as a single treatment.  
Supplementary laser treatments are allowed during the  study.  Retreatment 
with laser is allowed if both of the following criteria are met:  
 Presence of ROP requiring treatment  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 13 of 66 
CONFIDENTIAL   Fundus examination reveals area for additional laser treatment 
as judged by [CONTACT_093] (fundus photography 
recommended to help w ith adjudication)  
Rescue treatment with aflibercept 0.4 mg/0.01 mL is allowed if the fundus 
examination reveals that laser treatment is complete as judged by [CONTACT_801511] 1 of the following conditions is met:  
 Worsening of ROP compared to the mos t recent pre -laser 
examination  
 Persistence of ROP requiring treatment  
Patients who initiate aflibercept rescue treatment may receive additional 
aflibercept  injections according to the aflibercept group treatment regimen.  
Endpoint(s)   
 Primary:  The primary endpoint is the proportion of patients with absence of active 
ROP and of unfavorable structural outcomes at week [ADDRESS_1106420] meet  the endpoint.  
Unfavorable structural outcomes are defined as retinal detachment, macular 
dragging, macular fold, or retrolental opacity.  
 Secondary:  The secondary endpoints are:  
 Proportion of patients requiring intervention with a second 
treatment modality from baseline to week 52 of chronological 
age 
 Proportion of patients with recurrence of ROP through 
week  52 of chronological age  
 The proportion of patients with treatment -emergent adverse 
events (TEAEs) and serious adverse events (SAEs) (ocular 
and systemic) from baseline to week 52 of chronological age  
Procedures and Assessments  The efficacy procedures/assessments include:  Posterior segment 
assessment, indirect ophthalmoscopy, color fundus photographs using wide -
field digital retinal photography, visual function, retinoscopy, and ocular 
motility.  
The safety procedures/assessments include:  ophthalmic examinations, 
intraocular pressure, physical examination, vital signs, clinical laboratories, 
and central nervous system imaging.  
The s tudy also includes pharmacokinetic, anti -drug antibody, and biomarker 
assessments.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 14 of 66 
CONFIDENTIAL  Statistical Plan  Statistical Hypothesis:  
This study will examine the following hypothesis for the primary efficacy 
variable regarding the proportion of patients with absence of active ROP and 
unfavorable structural outcomes at week 52 of chronological age.  Statistical 
testing will be conducted to demonstrate the non -inferiority of the 
aflibercept group to the laser group, with a non -inferiority margin of 5% and 
a significance  level of 5% (one -sided test).  
H0:  p t = p c - 5% versus H 1:  p t ≥ p c - 5% 
where p t is the true proportion of patients with absence of active ROP and 
unfavorable structural outcomes at week 52 of chronological age for the 
aflibercept group, and p c is the true proportion of patients with absence of 
active ROP and unfavorable structural outcomes at week 52 of 
chronological age for the laser group.  
The proposed non -inferiority margin of 5% is smaller than the smallest 
difference between laser and ranibizumab in the RAINBOW study (a 
phase  [ADDRESS_1106421] of IVT ranibizumab to laser in the 
management of ROP) , and not greater than the diffe rence between the 2 
ranibizumab doses.  
Justification of Sample Size:  
From the RAINBOW study, the response rate was 66.1% for the laser group 
and 88.1% for the 0.[ADDRESS_1106422] up to 100% (with at 
least 2 studies demonstrating a 100% response rate in terms of favorable 
anatomic structural outcomes/prevention of unfavorable anatomic structural 
outcomes) w ith intravitreal aflibercept dose s ranging from  0.4 mg to 1 mg. 
An estimated 90% response rate for the aflibercept group and 66.1% 
response rate for the laser group would be a reasonable  assumption.  It is 
assumed that the proportion of patients with out active ROP will be in line 
with this.  A sample size of 84 patients in the aflibercept group and 
28 patients in the laser group (randomized in a 3:1 ratio) will provide 92% 
power for rejecting the null hypothesis at a 1 -sided 5% significance level.  
Statistic al Methods:  
Unless stated otherwise, all variables will be analyzed descriptively with 
appropriate statistical methods:  continuous variables by [CONTACT_358049] 
(ie, mean, standard deviation, median, quartiles, minimum, and maximum), 
and categorical vari ables by [CONTACT_22977].  
Efficacy Analyses:  
The primary and secondary efficacy variable analyses will be conducted on 
the FAS.  The primary analysis is a statistical evaluation of non -inferiority 
of aflibercept vs. laser at week [ADDRESS_1106423] to the 
primary efficacy variable. The non -inferiority margin is set at 5%.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106424] (LOCF) to the EOS visit for analysis.  If the patient 
discontinued at or before this visit, no data will be carried forward and the 
patient wi ll be considered a non -responder.  For patients with both eyes 
enrolled in the study, both eyes must meet the endpoint.  Patients with only 
one study eye enrolled will be responders if the respective eye responds.  
The statistical analysis will be performed  using the Cochran -Mantel -
Haenszel method stratified by [CONTACT_801512]. The 1-sided 95% 
Mantel -Haenszel confidence intervals using normal approximation of the 
difference of response rates between the aflibercept group and the laser 
group will be calcu lated.  Aflibercept will be considered to be non -inferior 
to laser if the confidence interval of the difference lies entirely above -5%. 
Furthermore, eyes will be considered to be non -responders if rescue 
treatment is given.  The primary analysis for this endpoint will be based on 
the investigator assessment of, and sensitivity analyses based on the cent ral 
RC data will be conducted.  
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 16 of 66 
CONFIDENTIAL  1. INTRODUCTION  
Retinopathy of prematurity (ROP) is a proliferative vascular retinopathy caused by [CONTACT_801513] (Mutlu, 2013 ) 
(Pertl, 2015 ) (Salman, 2015 ).  It mainly affects newborns with a preterm gestational age 
(≤32  weeks) and very low birth weight (≤1500 g).  Approximately 10% to 11% of all newborn 
infants are born preterm (Blencowe, 2013 ) (Hellström, 2 013).  Among premature infants, the 
incidence of ROP ranges from 20% to 30%, increasing for younger gestational ages.  The 
prevalence of blindness caused by [CONTACT_801514] 6% and 18%, while 
in developi[INVESTIGATOR_801496] >20 % (Hartnett -1, 2014 ) (Gilbert, 1997 ).  Epi[INVESTIGATOR_801497], such as oxygen exposure (Hartnett -2, 2014 ).  The first wave of ROP cases, in the 1940s 
and 1950s, were identified in preterm infants who were exposed to high levels of supplementa l 
oxygen in closed incubators, causing abnormal development of the vascular network in the 
premature retina.  Stricter control of supplemental oxygen led to a decreased incidence of this 
condition (Hellström, 2013 ).  An English study showed that the incidence of ROP later increased 
from 12.8 per 1000 low birth -weight infants in 1990 to 125.5 per 1000  low-birth -weight infants in 
2011 (Painter, 2015 ).  This second wave of ROP cases may be attributed to improved survival of 
the most extremely premature infants, introducing a new population of vulnerable newborns more 
susceptible to ROP.  
Vascular endothelial growth factor (VEGF) is up -regulated und er ischemic conditions.  As ROP 
is characterized by [CONTACT_801515], it has also been 
associated with increased levels of VEGF.  Vascular endothelial growth factor -A (VEGF -A) is a 
member of the VEGF family of a ngiogenic factors that acts through activation of the receptor 
tyrosine kinases vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial 
growth factor receptor 2 (VEGFR2) to increase mitosis, chemotaxis, and vascular permeability in 
endothelial cells.  Upregulation of VEGF -A due to ischemia in the avascular retina may induce 
pathologic neovascularization and subsequently lead to retinal detachment and blindness, as seen 
in late -stage ROP (Stone, 1996 ) (Young, 1997 ).  Aflibercept inhibits these effects of VEGF by 
[CONTACT_52999] a soluble decoy receptor that binds VEGF -A with higher affinity than the natural 
receptors and thereb y inhibits the binding and activation of these cognate VEGF receptors.  
Aflibercept also inhibits the effects of placental growth factor, which binds only to VEGFR1. 
Placental growth factor can synergize with VEGF -A, enhancing these processes of pathologic  
neovascularization, and is also known to promote leukocyte infiltration and vascular inflammation.  
Based on the its mode of action, aflibercept has a high potential to become an effective treatment 
option for the treatment of ROP, and several reports of off-label clinical use have shown positive 
efficacy outcomes without indicating new safety concerns (Sukgen, 2018 ) (Salman, 2015 ) 
(Huang,  2018 ). 
In addition to the evidence currently available for aflibercept, the efficacy and safety of anti -VEGF 
agents for the treatment of ROP have been compared to laser in several case series a nd 2 large 
randomized controlled trials (BEAT -ROP and RAINBOW).  The totality of the clinical evidence 
available thus far indicates a trend towards superior prevention of unfavorable anatomical 
outcomes for anti -VEGF agents compared to laser for ROP in cen tral retinal locations (Zone I with 
any ROP stages without plus disease, or Zone I stage 3 without plus disease, or Zone II with 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 17 of 66 
CONFIDENTIAL  stages  2 plus or 3 plus disease), a nd aggressive posterior ROP (AP -ROP), and establishes the proof 
of concept for this indicati on (Mintz -Hittner, 2011 ) (Harder, 2013 ) (Hwang, 2015 ). 
Aflibercept has been previo usly studied for several adult indications characterized by [CONTACT_801516], and is approved in 
multiple countries for treatment of indications such as diabetic retinopathy (DR), neovascul ar 
age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal 
venous occlusion and choroidal neovascularization secondary to pathological myopia.  
Considering the consistently positive outcomes provided by [CONTACT_801517] -mediated indications, it is deemed appropriate to conduct a study for a pediatric VEGF -
mediated indication for the treatment of ROP.  
Additional background information on the study drug and development program can be found in 
the Investi gator’s Brochure.  
2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective of the study is to assess the efficacy of aflibercept compared to laser in 
patients diagnosed with ROP.  
2.2. Secondary Objectives  
The secondary objectives of the study are:  
 To assess the  need for a second treatment modality  
 To assess the recurrence of ROP  in the study  
 To assess the safety and tolerability of aflibercept  
2.3. Exploratory Objectives  
The exploratory objectives of the study are:  
 To further characterize the anatomical effects of treatment with aflibercept in patients 
with ROP  
 To further investigate the study intervention (eg, mode -of-action -related effects and/or 
safety) relevant to this disease process  
 To assess the treatment burden of aflibercept and laser  
 To characterize the co ncentrations of free and bound aflibercept in plasma over time  
To describe the potential immunogenicity of aflibercept  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 18 of 66 
CONFIDENTIAL  3. HYPOTHESIS AND RATIO NALE  
3.1. Hypothesis  
Intravitreal aflibercept dosed at 0.4 mg will achieve comparable results as assessed by [CONTACT_798435] (absence of active ROP and of unfavorable structural outcomes) when compared to laser 
therapy.  
3.2. Rationale  
3.2.1.  Rationale for Study Design  
Laser photocoagulation of the peripheral avascular retina is the current standard of care for the 
treatment of ROP.   Considering aflibercept’s mode of action, and the current clinical evidence  
describing positive outcomes in ROP with off -label use of anti -VEGF in central retinal disease or 
AP-ROP, a randomized clinical trial to compare the ability of these treatments t o manage active 
ROP and prevent the development of ocular complications is warranted.  
The substantial amount of existing data describing outcomes of laser in ROP is sufficient to 
provide an accurate understanding of the potential benefits and limitations o f this treatment 
modality.  The purpose of the current study is primarily to collect the missing data on the outcomes 
of aflibercept in the treatment of ROP, and for this reason, a 3:1 randomization design is planned.  
Additionally, a fully -masked study of  intravitreal (IVT) aflibercept compared to laser is technically 
unfeasible.  
The inclusion and exclusion criteria allow the selection of an appropriate patient population and 
increase the likelihood of producing reliable and reproducible results, while gua rding against 
exploitation of vulnerable patients.  The proposed criteria are based on existing clinical knowledge 
and feedback from key opi[INVESTIGATOR_801498].  
3.2.2.  Rationale for Dose Selection  
Currently available cli nical data  (Sukgen, 2018 ) (Salman, 2015 ) (Sidorenko, 2018 ) consistently 
show promi sing efficacy, with no identification of major safety concerns, when using aflibercept 
doses ranging from 0.4 mg to 1 mg per eye (ie, 1/5 to 1/2 of the 2 mg dose approved for indications 
in adult patients).  In order to limit drug exposure, the lowest dose  for which positive efficacy was 
reported (0.4 mg/0.01 mL) was selected for this study.   An injection volume of 0.01 mL is 
considered acceptable for IVT administration  in infants . 
3.3. Risk -Benefit  
Aflibercept is marketed for the treatment of adult patients wit h several retinal diseases that are 
characterized by [CONTACT_114273] -induced upregulation of VEGF, are related to pathological 
neovascularization and/or vascular leakage, and can result in retinal thickening and edema, which 
are thought to contribute to vision lo ss.  The efficacy and safety of IVT aflibercept used in adult 
patients with retinal diseases are well established, and its risk -benefit profile is considered 
favorable.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 19 of 66 
CONFIDENTIAL  Inhibition of VEGF activity by [CONTACT_801518], since ROP is also characterized by [CONTACT_801519].  Aflibercept has 
demonstrated efficacy in animal models of pathological ocular ne ovascularization after systemic 
and IVT administration.  No differences in the mechanism of action of aflibercept in the treatment 
of neovascular ocular diseases between children (eg, ROP) and adults are expected.  There is a 
high and unmet medical need fo r an effective, safe, and approved treatment for preterm infants 
with vision -threatening ROP, a disease that is a leading cause of blindness in both developi[INVESTIGATOR_801499].  Laser (for the peripheral early stage of ROP) is currently considered a 
standard of care, but fails to achieve a normal retinal structure in up to 25% of ROP patients with 
central retinal disease or AP -ROP.  Additionally, laser is associated with potential risks, including 
irreversible loss of visual field and high myopia.  Vitreoretinal surgery is reserved for advanced 
disease stages with retinal detachment (stages 4 and 5).  Increasi ng clinical experience from 
off-label use of IVT aflibercept for central ROP suggests positive efficacy outcomes, usually after 
a single injection, with no major safety concerns as currently reported.  Thus, aflibercept has the 
potential to offer improved outcomes in this high -risk, vuln erable premature newborn population 
with ROP.  
3.3.1.  Known and Expected Benefits  
Aflibercept is expected to provide demonstrable anatomical benefits through regression of ROP 
features while allowing the vascularization to resume its usual development towards the retinal 
periphery, thus preventing unfavorable structural outcomes in approximately 90% of treated 
patients.  Visual function is also expected to improve (preservation of peripheral visual field, 
prevention of loss of best corrected visual acuity, and lowe r proportion of patients developi[INVESTIGATOR_801500]).  
Moreover, additional advantages of aflibercept over laser treatment are expected.  An aflibercept 
injection is less time -consuming than laser (an IVT injection is often less than 30  minutes, whereas 
laser treatment may take 2 or more hours).  Laser treatment requires general anesthesia/sedation, 
risks that would be largely  avoided when using aflibercept.  Aflibercept treatment may be given 
regardless of the patient's ocular anatomy (while laser treatment would be difficult in patients 
without adequate visualization of the retina, such as in patients with hazy corneas, iris 
neovascularization, or small pupi[INVESTIGATOR_8324]).  Aflibercept treatment of fers the potential for a 
single -injection treatment option and can be administered immediately after diagnosis and 
informed consent by [CONTACT_7071](s)/legally authorized representative(s).  Bilat eral cases can be 
treated in a single session.  Upon recurrence of vision -threatening ROP, re -treatment with the same 
dose may be given to each treatment -requiring eye, after injection -free intervals of at least 28  days.  
For laser, once avascular retina a blation is complete, re -treatment may not offer additional benefits.  
In addition to all this, laser treatment is more susceptible to operator -dependent differences with 
the possibility of having significant areas of untreated retina, consequently increasi ng the risk of 
failure.  Achieving adequate laser treatment depends on the experience and ability of an individual 
practitioner.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 20 of 66 
CONFIDENTIAL  3.3.2.  Potential Risks and Mitigation Measures  
Based on the cumulative safety experience with aflibercept for the treatment of adult p atients with 
retinal diseases, the potential risks for the study patients include  those described below.  
[IP_ADDRESS].  Ocular Risks  
Ocular risks include intraocular inflammation (including endophthalmitis), retinal tear/ 
detachment, transient intraocular pressure increa se, and traumatic cataract.  
Patients with relevant ongoing or significant previous use of systemic steroids at 
immunosuppressive  levels are excluded, to mitigate any potential increased risk of local or 
systemic infections, and to address any potential ris k of worsening clinical conditions that have 
been historically reported in the context of steroid use in preterm infants, such as more frequent or 
greater incidence rates of necrotizing enterocolitis, cerebral palsy, and gastrointestinal ulcer.  
[IP_ADDRESS].  Hypersensit ivity/Immunogenicity  
Hypersensitivity/immunogenicity (inherent to all therapeutic proteins) is addressed by [CONTACT_801520] (see Section 7.2.2 ). 
[IP_ADDRESS].  Acute Systemic Effects  
A minimum weight (800 g) at the time of study treatment (see Section  7.2.1 ) is required.  At this 
minimum weight, a patient in the aflibercept group  will receive 1 mg/kg when dosed bilaterally.  
This dose is predicted to increase systemic exposure in preterm infants when compared to adults  
receiving IVT treatment with aflibercept , but to remain  below limits determined in adult nAMD 
patients after intravenous dosing of aflibercept with a maximal tolerated dose of 1  mg/kg .  Patients 
will be monitored for any evidence of arterial hypertension, proteinuria, worsening of concomitant 
conditions typi[INVESTIGATOR_19529] l for preterm infants (eg, worsening of intraventricular hemorrhage I or II, other 
non-ocular hemorrhages), or arterial thromboembolic events.  Pharmacokinetic (PK) samples for 
the measurement of systemic aflibercept concentrations (both free aflibercept [ the 
pharmacologically active form] and aflibercept bound to VEGF [the inactive form]) will be taken.  
The study population is vulnerable, due to their underlying prematuri ty, to increased risk for 
multi -organ comorbidities (such as bronchopulmonary dysplas ia, intraventricular hemorrhage, 
necrotizing enterocolitis, septic conditions), and developmental delays, compared to term infants.  
Given the high unmet medical need, the potential to more effectively treat ROP with a single 
injection ( or possibly up to 3  injections), and the risks associated with laser treatments, the 
potential lifelong benefits to children treated with aflibercept outweigh the potential risks, and the 
expected risk -benefit profile is favorable.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106425] meet the endpoint.  
Unfavorable structural outcomes are defined as retinal detachment, macular dragging, macular 
fold, or retrolental opacity.  
4.1.2.  Secondary Endpoints  
The secondary endpoints are:  
 Proportion of patients requiring intervention with a  second treatment modality from 
baseline to week  52 of chronological age  
 Proportion of patients with recurrence of ROP through week 52 of chronological age  
 The proportion of patients with treatment -emergent adverse events (TEAEs) and 
serious adverse events  (SAEs) (ocular and systemic) from baseline to week 52 of 
chronological age  
4.1.3.  Exploratory Endpoints  
The exploratory endpoints are:  
 The number of aflibercept administrations from baseline to week 52 of chronological 
age 
 The number of laser treatments from baseline to week 52 of chronological age  
 The proportion of patients needing more than 1 aflibercept injection through week  52 
of chronological age  
 The proportion of patients/eyes need ing more than 1 laser treatment  through week  52 
of chronological age  
 Time  to recurrence of ROP  
 Time to intervention with a second treatment modality for ROP or to development of 
unfavorable structural outcomes  
 Completion of vascularization of the peripheral retina to within 1 disc diameter of the 
ora serrata on FP at week 52 of  chronological age  
 Assessment of retinal vascularization and leakage on fluorescein angiography (FA) at 
week  52 of chronological age in patients participating in the FA substudy  
 Time to completion of retinal vascularization  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 22 of 66 
CONFIDENTIAL   Regression of plus disease, regr ession of pre -retinal vascularized ridge, and progression 
of retinal vascularization beyond the ridge from baseline to week 52 of chronological 
age 
 Progression to stage 4 or 5 ROP from baseline to week 52 of chronological age  
 Evaluation of visual function at week 52 of chronological age  
 Time required to perform aflibercept injec tion or initial laser treatment  
 Requirement for sedation and/or general anesthesia to complete laser or aflibercept 
injection  
 Number of visits required up to week 52 of chronological  age 
 Systemic exposure to free and bound aflibercept (at expected maximum plasma 
concentration and during the elimination period from plasma) determined by [CONTACT_801521]  
 To assess immunogenicity as incidence of treatment emergent antibodies to aflibercep t 
in patients over time.  
5. STUDY VARIABLES  
5.1. Demographic and Baseline Characteristics  
Baseline characteristics will include standard demography (eg, age, race, weight, height, etc.), 
disease characteristics, medical history, and medication history , as well as  relevant maternal 
history, for each patient.  
5.2. Efficacy Variables  
The efficacy variables relevant to the primary endpoint are ROP status and ocular anatomy.  
The efficacy variables relevant to the secondary endpoints are:  
 Intervention with a second treatment modality  
 Recurrence of ROP  
The efficacy variables relevant to the exploratory endpoints are:  
 Exposure:  
 Number of aflibercept injections  
 Number of laser treatments  
 Number of rescue treatments  
 Number o f visits  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 23 of 66 
CONFIDENTIAL   Time  
 To recurrence of ROP  
 To intervention with  second modality or development of unfavorable structural 
outcomes  
 Needed to perform aflibercept injection and initial laser treatment  
 Assessment of retinal vasculature and ROP status with fundus exam, FP and FA (for 
those participating in FA substudy), in cluding time to completion of retinal vasculature  
 Assessment of visual function  
 Need for sedation  and/or general anesthesia  
5.3. Safety Variables  
The safety variables are:  
 Adverse events (TEAEs and SAEs)  
 Ophthalmic examinations  
 Physical examinations  
 Vital signs  
 Clinical laboratories  
 Central nervous system imaging  
5.4. Pharmacokinetic Variables  
The PK variable is the concentration of free or bound aflibercept.in plasma at each time point.  
Samples in this study will be collected using a sparse sampling schedule (eg, only 1 blood sample 
for drug concentration assessment will be collected at any si ngle clinic visit).  These sampling time 
points are specified in Table  1. 
5.5. Immunogenicity Variables  
Anti-drug antibody variables will include ADA status (positive or negative), titer, and neutralizing 
antibody  (NAb) status for analyzed samples collected at the time points specified in Table  1. 
5.6. Biomarker Variables  
The biomarker variables may include those relevant to diagnostic, safety, pharmacodynamics, 
monitoring, or potentially predictive biomarkers.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron  Pharmaceuticals, Inc.   Page 24 of 66 
CONFIDENTIAL  6. STUDY DESIGN  
6.1. Study Description and Duration  
This is a phase 3, multicenter, randomized, 2 -arm, open -label clinical study to assess the efficacy, 
safety, and tolerability of IVT aflibercept versus laser in patients with ROP .  The study consists of 
screening/baseline (1 or 2 visits), a treatment period (including potential retreatment and rescue 
treatment), an d a final visit at week 52 of chronological age ( Figure  1). 
The study also includes an optional fluorescein angiography  (FA)  sub-study ( Appendix  1), which 
includes optional FA at baseline, and mandatory FA at week 52 of chronological age.  
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 25 of 66 
CONFIDENTIAL  Figure  1: Study Flow Diagram  
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106426] 1  eye with 
1 of the following retinal findings:  
 Zone I Stage 1 plus, 2 plus, 3 non -plus or 3 plus, or  
 Zone II Stage 2 plus or 3 plus, or  
 AP-ROP  
One or both eyes can be treated according to the investigator’s assessment of the study’s eligibility 
criteria.  If both eyes are el igible, they will be assigned to the same treatment group.  The second 
eye of patients who start the study with only [ADDRESS_1106427] eye, the seco nd eye will be included in the efficacy 
analysis . 
Color fundus photography with digital wide -field images  (DWFI) of the  retina will be taken before 
any treatment is applied.  These images will be submitted to a central reading center (RC) as soon 
as possib le for confirmation of ROP staging, and if deemed eligible, treatment should be 
administered.  However, due to the urgency of treatment for this medical condition, in situations 
where the investigator considers that awaiting a response from the RC and thus  delaying treatment 
may be detrimental to the outcome, treatment is allowed to be administered immediately after the 
images are acquired, before availability of the RC confirmation of ROP staging.   In this case, the 
investigator's assessment of the images will be used in stratification.  
Patients will be randomized 3:1 to treatment with either aflibercept injection or laser, respectively.  
Aflibercept group : 
Patients randomized to aflibercept will receive a single IVT injection of aflibercept 
0.4 mg/0.01  mL p er eligible eye at baseline.  
Thereafter, if required, up to 2 additional IVT injections of aflibercept 0.4 mg/0.01 mL may be 
administered in each eye in case both the following retreatment criteria are met ( Figure  2): 
 Presence of ROP requiring treatment AND  
 The interval since the last aflibercept IVT injection is ≥28 days  
Rescue treatment with laser may be performed if 1 of the following conditions is met ( Figure  2): 
 Worsening of ROP compared to the examination immediately preceding the previous 
aflibercept  injection, during the 27  days following the aflibercept injection  
 Presence of ROP requiring treatment after the patient already received a to tal of 
3 aflibercept injections  
Once rescue treatment is applied, treatment with the patient’s randomized treatmen t cannot be 
reinitiated.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 27 of 66 
CONFIDENTIAL  Figure  2: Aflibercept Treatment, Aflibercept Retreatment, and Rescue Treatment  
 
Once rescue treatment is applied, treatment with the patient’s randomized treatment cannot be reinitiated . 
 
Laser Group : 
Patients randomized to laser will undergo treatment in each eligible eye at baseline.  Treatment 
will be applied to the entire avascular peripheral retina.  Treatment should be kept well away from 
the fovea. Laser ablation should be as complet e as possible.  It is recommended that fundus 
photographs (DWFI) should be obtained right after administration of laser treatment to look for 
“skip” areas, and if found, laser should be administered to those areas prior to the investigator 
deeming the lase r treatment as “complete.”  In case multiple sessions are necessary within 1 week 
from baseline, they will be counted as a single treatment.  
Supplementary laser treatments are allowed during the study.  Retreatment with laser is allowed if 
both of the foll owing criteria are met ( Figure  3): 
 Presence of ROP requiring treatment  
 Fundus examination reveals area for additional laser treatment as judged by [CONTACT_1275] (fundus photography recommended to help with adjudication)  
Rescue treatment with aflibercept 0.4 mg/0.01 mL is allowed if the fundus examination reveals 
that laser treatment is complete  as judged by [CONTACT_441885] 1 of the following con ditions 
is met ( Figure  3): 
 Worsening of ROP compared to the most recent pre -laser examination  
 Persist ence of ROP requiring treatment  
Patients who initiat e aflibercept rescue treatment may receive additional aflibercept  injections 
according to the aflibercept group treatment regimen.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 28 of 66 
CONFIDENTIAL  Figure  3: Laser Treatment, Laser Retreatment, and Rescue Treatment  
 
Once rescue treatment is applied, treatment with the patient’s randomized treatment cannot be reinitiated.  
 
Both Groups : 
Once rescue treatment is applied to an eye, treatment in that eye with the patient’s randomized 
treatment cannot be reinitiated.  However, the fell ow eye can still receive the patient’s randomized 
study intervention, if retreatment criteria are met.  
Patients will have mandatory evaluations at regular intervals during the study at the time points 
specified in  Table  1.  Patients receiving retreatment and/or rescue treatment will have mandatory 
evaluations 1 day, 1 week, and 4 weeks after the retreatment/rescue treatment to a given eye.  
Acquisition an d submission of DWFIs (eg, RetCam) to the RC is required at baseline and at 
weeks  1, 2, 3, 4, 12, and 24, at week 52 of chronological age, before each retreatment and/or rescue 
treatment, and 1 week and 4 weeks after each retreatment/rescue treatment.  Safety will be assessed 
through the evaluation of adverse events (AEs), ophthalmic and physical examinations (including 
assessment of acute tolerability post -dosing), vital signs, and laboratory tests.  Pharmacokinetic 
evaluations will investigate plasma c oncentrations of free and bound aflibercept.  The potential 
emergence of ADAs will also be evaluated by [CONTACT_801522] 12.  
Additional optional evaluation visits may be performed in accordance with the usual standard of 
care, as medically needed.  
A phase 3b extension study is planned to assess the long -term outcomes of patients who received 
study intervention in this study.  All treated patients will be offered an opportunity to participate 
until they are 5 years of age to assess ocular effects, and clinical and neurodevelopmental 
outcomes.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106428] completed the study if he/she has completed all phases of the study 
including the last visit at week [ADDRESS_1106429] patient for the primary 
outcome.  
6.2. Planned In terim Analysis  
No interim analysis is planned.  
6.3. Study Committees  
6.3.1.  Independent Data Monitoring Committee  
The aim of the safety assessments is to determine if the study shows unacceptable risks for the 
patients, and to discontinue the study if necessary.  The assessments will be performed by [CONTACT_440940] (DMC).  Detailed information regarding the DMC 
procedures will be explained in a separate DMC charter.  
7. SELECTION, WITHDRAWA L, AND REPLACEMENT O F 
PATIENTS  
7.1. Number of Patients Planned  
Approximately 112 patients are planned to be enrolled in a 3:1 ratio (approximately 84  in the 
aflibercept group and approximately 28 in the laser group).  
7.2. Study Population  
The study population will consist of male and female preterm infants with treatment -naïve ROP 
Zone I Stage [ADDRESS_1106430] meet the following criteria at screening and baseline to be eligib le for inclusion in 
the study:  
1. Gestational age at birth ≤32 weeks or birth weight ≤[ADDRESS_1106431] one eye as:  
 Zone I Stage 1 plus, or 2 plus, or 3 non -plus or 3 plus, or  
 Zone II Stage 2 plus or 3 plus, or  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 30 of 66 
CONFIDENTIAL   AP-ROP  
3. Weight at baseline (day of treatment) ≥800 g  
4. Male or female  
5. Signed informed consent from parent(s)/legally authorized representative(s) as described 
in Section  13.2, which includes compliance with the requirements and restrictions listed in 
the informed consent form (ICF) and in this protocol.  
7.2.2.  Exclusion Criteria  
A patient who meets any of the following criteria will be excluded from the study:  
1. Known or suspected chromosomal abnormality, genetic disorder, or syndrome  
2. Previous exposure to any IVT or systemic anti -VEGF agent, including maternal exposure 
during pregnancy and/or during breastfeeding  
3. Clinically significant neurological disease (eg, intraventricular hemorrhage grade  3 or 
higher, periventricular leukomalacia, congenital brain lesions significantly impairing optic 
nerve function, severe hydrocephal us with significantly increased intracranial pressure)  
4. Pediatric conditions rendering the infant ineligible for study intervention at baseline or for 
repeated blood draws as evaluated by a neonatal intensive care unit specialist and a study 
ophthalmologist  
5. Presence of active ocular infection within [ADDRESS_1106432] treatment  
6. Advanced stages of ROP with partial or complete retinal detachment (ROP stage 4 and 
stage  5) 
7. ROP involving only Zone III  
8. Ocular abnormalities that may interfere with the administrati on of study intervention or 
assessment of the study primary endpoint  
9. Postnatal treatment with oral or intravenous corticosteroids at an equivalent dose of 
prednisone ≥1 mg/kg/day for >[ADDRESS_1106433] study intervention  
10. Previous surgical  or nonsurgical treatment for ROP (IVT anti -VEGF injection, ablative 
laser therapy, cryotherapy, and vitrectomy)  
11. Participation of the patient or the mother in other clinical trials requiring administration of 
investigational treatments (other than vitamins  and minerals) at the time of screening, or 
within 30 days or 5 half -lives of administration of the previous study drug, whichever is 
longer  
7.2.3.  Rescreening of Screen Failures  
Screen failures are patients for whom informed consent has been obtained but who do not 
subsequently enter the study.  A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure patients to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to  queries from regulatory authorities.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 31 of 66 
CONFIDENTIAL  Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious pretreatment events.  
In general, re -starting the defined set of screening procedures to enable the “screen failure ” 
patient’s participation at a later time point is not allowed.  Thus, in general, participation of an 
initial “screen failure” patient at a later time point is not acceptable, except if the screening failure 
was triggered by [CONTACT_801523] 2 a nd/or 3, or by [CONTACT_801524] 4, 5, 8, 9, 
and/or 11, or if the inclusion/exclusion criteria preventing the patient’s initial attempt to participate 
have been changed via protocol amendment.  
Under any of the above exceptions, a patient may only be re -screened once, and only within 
[ADDRESS_1106434] meet all selection criteria at the re -screening visit.  In any 
case, the investigator has to ensure that the repeated screenin g procedures do not expose the patient 
to an unjustifiable health risk.  Also, for rescreening, the patient’s parent(s)/legally authorized 
representative(s) have to sign a new ICF, even if it was not changed after the patient’s previous 
screening.  
Rescreen ed patients should be assigned a new patient number.  
7.3. Premature Withdrawal from the Study  
A patient's parent(s)/legal guardian(s) has the right to withdraw the patient from the study at any 
time, for any reason, and without repercussion.  
The investigator an d/or sponsor have the right to withdraw a patient from the study if it is no longer 
in the interest of the patient to continue in the study, or if the patient’s continuation in the study 
places the scientific outcome of the study at risk (eg, if a patient is not able to follow study 
procedures).  An excessive rate of withdrawals would render the study uninterpretable; therefore, 
unnecessary withdrawal of patients should be avoided.  
Parent(s)/legal guardian(s) of patients who are withdrawn prematurely from t he study will be asked 
for the patient to complete the early termination visit, as described in Section  9.1.2 . 
7.4. Replacement of Patients  
Patients prema turely discontinued from the study will not be replaced.  
8. STUDY TREATMENTS  
8.1. Investigational and Reference Treatments  
Patients will be randomized 3:1 to receive treatment with an IVT injection of aflibercept 0.4  mg 
or laser.  
Aflibercept (at a concentration of 40  mg/mL) will be supplied in sterile, sealed, 3 ml glass vials.  
The injection volume will be 10  µL (0.01  mL) and will be administered to the patients by [CONTACT_801525].  Instructions on dose preparation are provided in the pharmacy manual.  
See Section  6.1 for aflibercept dosing strategies.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 32 of 66 
CONFIDENTIAL  Transpupi[INVESTIGATOR_801501], sedation, or gen eral 
anesthesia, with appropriate respi[INVESTIGATOR_801502] (eg, laryngeal mask, endotracheal 
intubation, or similar), and administered according to standard local procedures.  The pupil of the 
eye to be treated must be dilated (mydriasis) with 2  or 3 drops of mydriatic agent(s) applied 
topi[INVESTIGATOR_801503], according to local practice.  
Laser power settings should be defined according to the investigator’s practice and applicable 
medical standards at the site.  The treatment should cover the entire av ascular retina, using a 
confluent laser pattern and extending to the ora serrata.  
See Section  6.[ADDRESS_1106435] be recorded on the respective electronic case report form (eCRF) page.  
All patients requiring rescue treatment wil l be counted as non -responders in the primary endpoint.  
Nevertheless, the patients should be followed to assess the efficacy and safety outcomes after 
rescue treatment.  
8.3. Dose Modification and Study Treatment Discontinuation Rules  
8.3.1.  Dose Modification  
Dose mod ification for an individual patient is not allowed.  
8.3.2.  Study Drug Discontinuation  
Patients who permanently discontinue from study drug should be encouraged to remain in the 
study.  Those who agree and do not withdraw from the study  will be asked to return to the clinic 
for all remaining study visits per the visit schedule.  
Patients who permanently discontinue from study drug and who opt to withdraw from the study 
will be asked to complete study assessments, per Section  9.1.2 . 
8.4. Method of Treatment Assignment  
Eligible patients will be randomized 3:[ADDRESS_1106436] specified 
by [CONTACT_456]'s responsible statistician and provided by [CONTACT_456]'s randomization management 
group.  To prevent imbalances, the randomization result of patients who do not complete baseline 
treatment wil l be assigned to a subsequent patient once it is known that the baseline treatment was 
not completed.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 33 of 66 
CONFIDENTIAL  Patients will be centrally assigned to randomized study intervention using an Interactive Voice 
Response System/Interactive Web Response System (IVRS/IWRS ).  Before the study is initiated, 
the telephone number and call -in directions for the IVRS and/or the log in information and 
directions for the IWRS will be provided to each site.  The investigator will provide the 
IVRS/IWRS with study center identificati on, the patient´s date of birth (DOB), gender, and weight 
at birth.  The complete DOB (day, month, and year) will be entered if allowed by [CONTACT_801526]’s chronological and corrected 
age during the study.  Because of the particular population in this study, absence of an exact DOB 
will cause a 30 -day deviation, resulting in possible misinterpretation of results and confounding 
the ability  to understand the outcomes, as this is usually c ompared with controls matched for the 
same corrected gestational age.  Additional details are documented in the IVRS/IWRS instruction 
manuals.  Study intervention will be dispensed at the study visits summarized in Table  1. 
8.5. Masking  
This is an open -label study where the study sites, the study team and the patient and patient’s 
parent(s)/legally authorized representative(s) know the treatment the patient is being given .  
Potential bias will be reduced by [CONTACT_801527].  Any aggregated 
treatment -specific data will be kept strictly confidential and will not be communicated to 
investigators.  
8.6. Treatment Logistics and Accountabili ty 
8.6.1.  Packaging, Labeling, and Storage  
Open -label study drug will display the product lot number on the label.  Each vial of study drug 
will be labeled per country requirements.  
Study drug will be stored at the site at a temperature of 2ºC to 8ºC; storage ins tructions will be 
provided in the pharmacy manual.  
8.6.2.  Supply and Disposition of Treatments  
Study drug will be shipped at a temperature of 2ºC to 8ºC to the investigator or designee at regular 
intervals or as needed during the study.  At specified time points during the study (eg, interim site 
monitoring visits), at the site close -out visit, and following drug reconciliation and documentation 
by [CONTACT_25007], all opened and unopened study drug will be destroyed/ returned to the sponsor 
or designee.  
8.6.3.  Treatmen t Accountability  
All drug accountability records must be kept current.  
The investigator must be able to account for all opened and unopened study drug.  These records 
should contain the dates, quantity, and study medication  
 dispensed to each patient  
 return ed from each patient (if applicable), and  
 disposed of at the site or returned to the sponsor or designee.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106437] be made available for inspection by [CONTACT_25008]; photocopi[INVESTIGATOR_24897].  
8.6.4.  Treatment Compliance  
Study intervention will be administered by a qualified ophthalmologist.  Details of aflibercept 
injection and of the laser procedure will be recorded in the eCRF (eg, time required, type of 
anest hesia, presence or absence of endotracheal intubation, treatment site).  
All drug compliance records must be kept current and made available for inspection by [CONTACT_25009].  
8.7. Concomitant Medications  
All medications the patient  received prior to visit 1 and any medication or vaccine (including any 
sedation, anesthesia, eye drops used for the study procedures, blood -derived products, prescription 
or over -the-counter medicines, probiotics, vitamins, and herbal supplements) that th e patient is 
receiving at the time of enrollment or receives during the study should be recorded along with:  
 The reason for use  
 Dates of administration including start and end dates  
 Dosage information including dose and frequency  
The use of medications, re creational drugs, or similar substances during pregnancy will be 
recorded on the Maternal Prior Medication section on the eCRF at screening (eg, alcohol, tobacco, 
antibiotics, corticosteroids, vaccination, supplements).  For breastfeeding mothers, all mate rnal 
medication or similar products taken after the umbilical cord clampi[INVESTIGATOR_801504]’s judgm ent.  The Medical Monitor should be 
contact[CONTACT_31182].  
8.7.1.  Prohibited Medications  
Exposure to any IVT or systemic anti -VEGF agent is not allowed in patients or in mothers who 
are breastfeeding.  
8.7.2.  Permitte d Medications  
The use of phototherapy lamp for treating jaundice is allowed.  Appropriate eye protection must 
be provided to the patient.  The use of phototherapy for jaundice will be documented in the eCRF, 
including the use of eye protection.  
The use of oxygen supplementation will be recorded in the corresponding eCRF section with 
special consideration of the method, concentration, duration of administration and the patient´s 
oxygen saturation by [CONTACT_801528].  In the last visit of the 
study, it will be recorded if oxygen supplementation is required.  Standard of care treatment for 
other conditions affecting patients is permitted.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106438]-study Treatments  
A phase 3b extension study is planned to assess the long -term outcom es of patients who received 
study intervention in this study and accept participation in the extension study.  No study treatment 
will be required or provided by [CONTACT_801529].  In case any treatment for ROP 
is required during the exte nsion study, the site’s standard of care should be administered.  Patients 
will undergo safety and efficacy assessments until 5 years of age.  
The baseline visit of the extension study can be conducted concomitantly with the week  52 
chronological age visit of this study.  
9. STUDY SCHEDULE OF EV ENTS AND PROCEDURES  
9.1. Schedule of Events  
Study assessments and procedures are presented by [CONTACT_25010]  1. 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 36 of 66 
CONFIDENTIAL  Table  1: Schedule of Events  
Visit Number1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
EOS  Retreatment or  
rescue treatment follow -up visits  
Visit Name1 SCR  BL D1 W1 W2 W3 W4 W6 W8 W10  W12  W16  W20  W24  W40  
CA W52  
CA TRT 
Visit  D1 
FUP  1W 
FUP  4W 
FUP  
Visit Window  -- -- +2D ±3D ±3D ±3D +7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±10D  ±10D  -- +2D ±3D +7D 
Informed consent  X                    
In/exclusi on criteria  X X                   
Enroll (IV RS/IWRS)   X                   
Demographi c X                    
Medical hi story2 X                    
Prior/conc omitant 
medication3 X X X X X X X X X X X X X X X X X X X X 
AEs X X X X X X X X X X X X X X X X X X X X 
Body weight  X X X X X X X X X X X X X X X X X X X X 
Head circumference and 
body length  X        X   X  X X X     
Hearing test  X4                    
CNS imaging  X5                    
Physical exam6 X X X X X X X X X X X X X X X X X X X X 
Vital signs7 X X X X X X X X X X X X X X X X X X X X 
Anterior segment 
examination8 X X X X X X X X X X X X X X X X X X X X 
Binocular indirect 
ophthalmoscopy9 X X X X X X X X X X X X X X X X X X X X 
Tonometry10  X               X    
Digital wide -field retinal 
imaging11  X  X X X X    X   X  X X  X X 
Fluorescein angiography 
(for optional sub -study)12  X              X     
Blood sample for ADA 
(aflibercept group  only)13  X         X          
Blood sample for PK 
(aflibercept group  only)14   X  X  X              
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 37 of 66 
CONFIDENTIAL  Visit Number1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
EOS  Retreatment or  
rescue treatment follow -up visits  
Visit Name1 SCR  BL D1 W1 W2 W3 W4 W6 W8 W10  W12  W16  W20  W24  W40  
CA W52  
CA TRT 
Visit  D1 
FUP  1W 
FUP  4W 
FUP  
Visit Window  -- -- +2D ±3D ±3D ±3D +7D ±7D ±7D ±7D ±7D ±7D ±7D ±7D ±10D  ±10D  -- +2D ±3D +7D 
 
Hematology, clinical 
chemistry, urinalysis15 X                    
Urine  protein test16  X X  X  X             X 
Aflibercept injection (for 
patients randomized to 
active)17  X     
          X    
Laser treatment (for 
patients randomized to 
control)18  X               X    
Visual function               X  X     
Refraction                 X     
Ocular extrinsic motility        
       X  X     
Abbreviations  CA = chronological age  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 38 of 66 
CONFIDENTIAL  9.1.1.  Footnotes for the Schedule of Events Table  
1. Additional visits may  be performed depending on the investigator’s assessment of the 
patient’s response to treatment, as part of local standard of care.   Visits [ADDRESS_1106439] at v isit 2, it can 
be administered within 3 days of v isit 2.  For Visits 3 to 14, the intervals are based on the 
date of initial treatment.  The intervals of the rescue/retreatment follow -up visits are based 
on the date of rescue/retreatment.  A retreatment/rescue follow -up visit  may be combined 
with a regularly scheduled visit .  If a patient’s second eye qualifies for treatment during the 
study, both eyes can follow the visit schedule of the first eye after the retreatment/rescue 
treatment follow -up visit schedule is completed fo r the second eye . 
2. Maternal and patient medical history will be recorded . 
3. Includes recording of oxygen supplementation.   At screening, include s any of the 
medications listed in Section  8.[ADDRESS_1106440] to be performed once, at any time prior to discharge from neonatal intensive 
care unit ( NICU ). 
5. Imaging is not required at screening if results from an imagi ng exam performed within the 
previous 10 days are available and there are no new neurological sign/symptoms.  A second 
CNS imaging is to be carried out prior to discharge from the N ICU. 
6. Includes cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurologic al systems according 
to local general practice and aiming to evaluate overall health.  
7. Temperature, blood pressure (before study treatment, if applicable), respi[INVESTIGATOR_696] , and pulse 
rate. 
8. Can be done using indirect ophthalmoscopy or portable slit lamp.  
9. The pup ils must be sufficiently dilated to allow examination of all ROP features .  
Unfavorable structural outcome is defined as retinal detachment, macular dragging, 
macular fold, or retrolental opacity.  
10. Only in patients receiving aflibercept.  The IOP will be me asured in both eyes prior to the 
injection, and at least once post -injection (only in treated eyes).  
11. Baseline imaging will be done prior to study treatment on the treatment day or up to 2  days 
prior to treatment.  Imaging at week 24 and/or week 52 of chron ological age may not be 
required if the following conditions are met:  the reading center assessment of 
morphological outcomes on the week [ADDRESS_1106441] 
ophthalmoscopy performed by [CONTACT_093], and the patient shows poor toler ance for 
the imaging procedure, preventing acquisition of images with adequate quality.  Cases of 
rescue/retreatment require additional imaging before any treatment (on the treatment day 
or up to 2 days prior to treatment) as well as 1 week and 4 weeks fol lowing rescue/ 
retreatment.  
12. Optional at baseline ; mandatory at week 52 of chronological age (visit 16 ). 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106442] anti -drug antibodies (ADAs) and, if applicable, the occurrence of potential 
neutralizing antibodies (NA b) (if c ollection is not possible, the week  12 sample can be 
taken at week 16). 
14. Only applicable for patients treated with aflibercept at baseline.  One blood sample each 
for plasma concentrations of study drug will be taken on day 1 (approximately 24  hours 
after dosing), day 14, and day 28.  Blood pressure must be measured before the PK sample 
is taken.  If a patient’s second eye is deemed eligible for treatment and is treated with 
aflibercept at visits 3, 5, or 7, the PK sample is taken before treatment.  
15. A sample is not needed if results from laboratory tests within 8 days prior to screening are 
availabl e and there was no change in the clinical situation from the time of the sample to 
the screening visit.  
16. The baseline sample can be taken up to 2 days prior to baseline.  The day 1 sample will be 
approximately 24 hours after study treatment.  
17. The injection s hould be performed in both eyes on the same day, if applicable.  After initial 
treatment, each study eye may receive up to 2 additional treatments (with a minimum 
interval of 28 days between injections) only if retreatment criteria are met.  After 
retreatm ent, the retreatment/rescue treatment follow -up visits are also required.  Blood 
pressure must be measured before the injection.  Details of each injection will be recorded 
in the eCRF.  
18. Multiple sessions performed within 1 week after baseline to complete t he procedure will 
be counted as a single treatment.  Each study eye may receive retreatment only if the 
retreatment criteria are met.  After retreatment, the retreatment/rescue treatment follow -up 
visits are also required.   Blood pressure must be measured before laser.  
9.1.2.  Early Termination Visit  
Patients who are withdrawn from the study before the primary endpoint visit (week 52 of 
chronological age) will be asked to return to the clinic:  once for an early termination visit 
consisting of the end of study asse ssments described in Table  1. 
9.1.3.  Unscheduled Visits  
All attempts should be made to keep patients on the study schedule.  Unscheduled visits may be 
necessary to repeat testing following abnormal laboratory results, for follow -up of AEs, 
management and/or follow -up of procedures performed in the observation phase of the study, or 
for any other reason, as warranted.  
Unscheduled visits for observation follow the list of assessments used for visit 8 (week 6).  In case 
treatment is required, the assessments listed in the retreatment visit will be performed.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 40 of 66 
CONFIDENTIAL  9.2. Study Procedures  
9.2.1.  Procedures Performed Only at the Screening/Baseline Visit  
Procedures performed onl y at the screening/baseline visits are:  Informed consent, inclusion/ 
exclusion criteria, demographics, medical history,  and collection of clinical laboratory samples  
(Table  1). 
9.2.2.  Efficacy Procedures  
All ophthalmic evaluations will be conducted according to the schedule detailed in Table  1. 
Posterior se gment assessment to confirm ROP staging or resolution will be evaluated by [CONTACT_801530] -field digital retinal photography (eg, 
RetCam, Phoenix ICON Camera).  
Indirect ophthalmoscopy will be performed accordin g to local medical practice and applicable 
medical standards at the site (eg, usually using a head -mounted light source and a 2 5- 28, or 
30-diopter lens).  For this examination, the pupil of the eye must be dilated (mydriasis) with topi[INVESTIGATOR_106014] m ydriatic eye drops to the eye.  
Clinically significant abnormal findings will be reported as AEs in the eCRF.  
Color fundus photographs using wide -field digital retinal photography have to be taken at the time 
points specified in Table  1. 
All images taken by [CONTACT_133758] -field digital retinal imaging photography during the study will be 
submitted to a central reading center to confirm the ROP staging or resolution, and analysis of 
efficacy data.  All images are part of the source data for the study  and must be retained by [CONTACT_422400].  A detailed protocol for color fundus photographs image acquisition and 
transmission can be found in the respective manual.  
[IP_ADDRESS].  Other Ocular Assessments  
With all ophthalmological examinations, abnormalities of th e retina or optic nerve as well as 
unfavorable ocular structural outcomes in each eye will be assessed.   All of the following ocular 
assessments are performed bilaterally  at the time points specified in Table  1. 
Visual function will be evaluated using a methodology appropriate for the age and development 
status of the child, including evaluation of fixation (eg, central, steady and maintained) and fixing 
and following a 5 -cm toy.  
Monocular and binocular evaluation of visual function has to be performed.  
If the patient is not able to cooperate with the above methods, another suitable method (eg, Visual 
evoked potentials) can be used to evaluate visual funct ion. 
Cycloplegic refraction will be measured with retinoscopy in each eye and reported separately for 
each eye.  
Ocular motility tests of both eyes (binocular testing) will be assessed to investigate the integrity of 
the extrinsic ocular muscles and their n erves (eg, Cover test or Hirschberg test).  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 41 of 66 
CONFIDENTIAL  9.2.3.  Safety Procedures  
[IP_ADDRESS].  Ophthalmic Examinations  
Assessments of ocular safety will include ophthalmologic assessment of the anterior and posterior 
segment (eg, by [CONTACT_314899]), and measurement of intraocular pressure (IOP), only 
in patients receiving aflibercept , at the time points specified in Table  1. 
All ophthalmic examinations are to be conducted in bot h eyes, unless otherwise indicated.  
Intraocular pressure will be measured only in patients receiving aflibercept using a portable 
tonometer (eg, Tono -Pen, Perkin’s Tonometer, or other locally approved device).  The same 
method of IOP measurement should be used in each patient throughout the study.  Intraocular 
pressure will be measured in both eyes prior to the injection , and only in the study eye(s) 
post-injection.  A local anesthetic may be topi[INVESTIGATOR_801505] (s) being tested (eg, 1 drop 
of oxybu procain).  
[IP_ADDRESS].  Physical Examination  
A routine physical examination will assess cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and 
neurological systems and will follow the standard practice of the site.  The assessment will be 
based on the clinical judgment of t he physician and aim to evaluate the overall health of the baby.  
Weight, body length, and head circumference will be measure as specified in Table  1. 
[IP_ADDRESS].  Vital Signs  
Temperature, heart rate, respi[INVESTIGATOR_697], and blood pressure (BP) will be measured according to 
the local medical practice and regulations , at the time points specified in Table  1.  Study staff 
trained in the assessment of infants will perform these assessments.  Blood pressure and heart rate 
should be assessed with a completel y automated device, appropriate for use in infants.  Blood 
pressure must be measured before any study treatment is administered and before PK sampling, if 
applicable.  
Clinically significant abnormal findings will be reported as AEs in the eCRF.  
[IP_ADDRESS].  Hearing Test 
The preferred hearing test will be a brainstem auditory evoked response (BAER), also referred to 
as an auditory brainstem response (ABR), using electrodes placed on the child’s head and ears to 
generate a response.  The choice of tool will consider th e child's age, degree of cooperation, and 
available resources. The child also should be comfortable with the testing situation.   Hearing will 
be assessed once, as specified in Table  1. 
[IP_ADDRESS].  Laboratory Testing  
The investigator must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the eCRF.  The laboratory reports 
must  be filed with the source documents.  Clinically significant abnormal laboratory findings are 
those that are not associated with the underlying disease, unless judged by [CONTACT_801531]’s condition.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106443] dose of study intervention should be repeated until the 
values return to normal or baseline or are no longer considered  clinically significant by [CONTACT_1275].  
 If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified and the sponsor 
notified  
 If laboratory values from non -protocol sp ecified laboratory assessments performed at 
the institution’s local laboratory require a change in patient management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in th e eCRF.  
Laboratory (hematology, chemistry, and urinalysis) analyses will be performed and reviewed at 
screening (visit 1).  A sample is not needed if results from laboratory tests within [ADDRESS_1106444] urine samples if possible.  
Additional samples, including A DA samples, may be collected at any time during the study as 
determined necessary by [CONTACT_11006].  This might be true for 
patients receiving rescue treatment with aflibercept.  
Samples for laboratory testing will be collected at visits according to Table  1.  Tests will include:  
Blood Chemistry  
Sodium  Total protein, serum  Total  bilirubin  
Potassium  Creatinine  Uric acid  
Chloride  Blood urea nitrogen (BUN)  Creatine phosphokinase (CPK)  
Carbon dioxide  Aspartate aminotransferase (AST)   
Calcium  Alanine aminotransferase (ALT)   
Glucose  Alkaline phosphatase   
Albumin  Lactate dehydrogenase (LDH)   
Hematology  
Hemoglobin  Differential:  
Hematocrit   Neutrophils  
Red blood cells (RBCs)   Lymphocytes  
White blood cells (WBCs)   Monocytes  
Red cell indices   Basophils  
Platelet count   Eosinophils  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106445] be repeated to confirm 
the nature and degree of the abnormality.  When necessary, appropriate ancillary investigations 
should be initiated.  If the abnormality fails to resolve or cannot be explained by [CONTACT_25037], the Medical/Study Director must 
be consulted.  
The clinical significance of an abnormal test value, within the contex t of the disease under study, 
must be determined by [CONTACT_093].  
Criteria for reporting laboratory values as an AE are provided in Section  10.1.1 . 
[IP_ADDRESS].  Central Nervous System Imaging  
Central nervous system ultrasound examinations will be performed by a well -experienced 
examiner , at the time points specified in Table  1.  The minimum source documentation will include 
electronic or paper documentation (medical report).  Other modalities of imaging (eg, magnetic 
resonance imaging) can be used instead of ultrasound if the alternative test was planned 
independently of the study.  
9.2.4.  Treatment of Overdose  
For this study, any instance where the investigator assumes that a single IVT dose of more than 
0.4 mg (0.01 mL) was administered will be considered an overdose.  Overdosing with increased 
injection volume may  increase IOP.  In these cases, evaluation of IOP and central retinal artery 
perfusion should be performed immediately after the injection and monitored until normalized.  If 
there is severe elevation of IOP causing disruption of central retinal artery per fusion, immediate 
measures to reduce IOP and restore central retinal artery perfusion (eg, performance of an anterior 
chamber paracentesis ) should be considered.  
Additionally, after ensuring that IOP and central retinal artery perfusion are in a safe range, the 
investigator should:  
1. Contact [CONTACT_27465]  
2. Closely monitor the patient for any further AE/SAE and laboratory abnormalities  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 44 of 66 
CONFIDENTIAL  3. Obtain a plasma sample for PK analysis if requested by [CONTACT_1689] (determined 
on a case -by-case basis)  
4. Document the quantity of the excess administered overdose in the eCRF  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_801532].  
9.2.5.  Drug Concentration and Measurements  
Since aflibercept levels are systemically demonstrable after IVT administration, systemic 
concentrations of study drug will be collected and described.  The PK evaluations will support the 
safety evaluation.  The object ives of the PK evaluations are to:  
 Describe the individual concentrations of free and bound aflibercept at several time 
points after the first IVT injection up to 4 weeks thereafter  
 Explore the potential influence of demographic and other factors on system ic 
aflibercept concentrations  
 Explore the relationship of systemic exposure and blood pressure  
PK sampling schedule (only applicable for patients treated with aflibercept at baseline)  
One blood sample each for plasma concentrations of study drug will be ta ken according to the time 
points in Table  [ADDRESS_1106446] date and time 
(24-hour clock) of all blood samples taken on the eCRF, as well as the exact time of the study 
intervention ad ministration.  
Details about the collection, processing, storage and shipment of samples will be provided 
separately in the laboratory manual.  No capi[INVESTIGATOR_801506].  
Additional samples may be collected at any time during the study as  determined necessary by [CONTACT_41161].  
9.2.6.  Immunogenicity Measurements and Samples  
Samples for ADA assessments will be collected at time points listed in Table  1. 
9.2.7.  Biomarker Procedures  
Blood pressure as a safety biomarker will be measured using an age -appropriate monitor at the 
time points shown in Table  1.  When applicable, measurements will be taken before study 
treatment, and before PK sampling.  
Only a very limited amount of blood is collected; leftovers (if any) may be used for additional 
research on study drug and/or disease.  Blood volume will not be increased for these research 
purposes.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106447] all clinical events occurring during the study data collection 
period (see Section  [IP_ADDRESS] ) from the time of signing the ICF or the first dose , to the end of the 
treatment period .  Medical conditions that existed or were diagnosed prior to the signing of the 
Informed Consent will be recorded  as part of medical history.  Abnormal laboratory values and 
vital signs observed at the time of Informed Consent should also be recorded as medical history.  
Any subsequent worsening (ie, any clinically significant change in frequency and/or intensity) of  
a pre -existing condition that is temporally associated with the use of the study drug should also be 
recorded as an AE.  
At each visit, the investigator will determine whether any AEs have occurred by [CONTACT_25040].  Adverse events may be directly  observed, reported spontaneously by [CONTACT_102]'s 
parent/legal guardian, or by [CONTACT_148749]'s parent/legal guardian at each study visit.  
Patient's parent/legal guardian should be questioned in a general way, without asking about the 
occurrence  of any specific symptoms.  The Investigator must assess all AEs to determine 
seriousness, severity, and causality, in accordance with the definitions in Section  10.2.  The 
Investigator’s assessment must be clearly documented in the site’s source documentation with the 
Investigator’s signature.  The Investigator should follow up on SAEs (and AESIs) until they have 
resolved or are considered clinically  stable; AEs should be followed until they are resolved or last 
study visit, whichever comes first.  
Always report the diagnosis as the AE or SAE term.  When a diagnosis is unavailable, report the 
primary sign or symptom as the AE or SAE term with additiona l details included in the narrative 
until the diagnosis becomes available.  If the signs and symptoms are distinct and do not suggest 
a common diagnosis, report them as individual entries of AE or SAE.   
Laboratory results, vital signs, and other diagnosti c result s or findings  should be appraised by [CONTACT_25042].   Isolated abnormal laboratory results, vital 
sign findings, or other diagnostic findings (ie, not part of a reported diagnosis) should be reported 
as AE s if they are symptomatic, lead to study drug discontinuation,  dose reduction,  require 
corrective treatment, or constitute an AE in the investigator ’s clinical judgment . 
For events that are serious due to hospi[INVESTIGATOR_059], the reason for hospi[INVESTIGATOR_31558] (diagnosis or symptom requiring hospi[INVESTIGATOR_059]).  A procedure is not 
an AE or SAE, but the reason for the procedure may be an AE or SAE.  Pre -planned (prior to 
signing the Informed Consent Form) procedure s, treatment s requiring hospi[INVESTIGATOR_801507]-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 46 of 66 
CONFIDENTIAL  pre-existing conditions that do not worsen in severity, and admission for palliative or social care 
should not be reported as SAEs (see Section  10.2 for Definitions).  
For deaths, the underlying or immediate cause of death should  always be reported as an SAE.  
Any SAE that may occur subsequent to the reporting period (end of the treatment  period) that the 
Investigat or assesses as related to study drug should also be reported.  
All AEs  and SAEs are to be reported according to the procedures in Section  10.1.3 . 
10.1.2.  Repo rting Procedure  
All events (serious and non -serious) must be reported with investigator’s assessment of the event’s 
seriousness, severity, and causality to the (when applicable: blinded) study drug.  For SAEs, a 
detailed narrative summarizing the course o f the event, including its evaluation, treatment, and 
outcome should be provided on the AE CRF.  Specific or estimated dates of event onset, treatment, 
and resolution should be included, when available.  Medical history, concomitant medications, and 
labora tory data that are relevant to the event should also be summarized in the narrative.  For fatal 
events, the narrative should state whether an autopsy was or will be performed, and include the 
results if available.  Information not available at the time of the initial report must be documented 
in a follow -up report.  Source documents  (including hospi[INVESTIGATOR_24925], diagnostic reports, 
etc.) will be summarized in the narrative on the AE CRF, and retained at the  study center and 
available upon request.  
Urgent safety queries must be followed up and addressed promptly.  Follow -up information and 
response to non -urgent safety queries should be combined for reporting to provide the most 
complete data possible within each follow -up.  
10.1.3.  Events that Require Expe dited Reporting to Sponsor  
The following events also require reporting to the sponsor (or designee) within 24 hours of learning 
of the event:  
 SAEs  
 AESIs:   No AESIs have been defined for this study  
10.2. Definitions  
10.2.1.  Adverse Event  
An AE is any untoward medical occurrence in a patient administered a study drug which may or 
may not have a causal relationship with the study drug.  Therefore, an AE is any unfavorable and 
unintended sign (including abnormal laboratory finding), symptom, or disease which is temporally 
associated with the use of a study drug, whether or not considered related to the study drug (ICH 
E2A Guideline.  Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994).  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106448] medical occurrence that at any dose:  
 Results in death  – includes all deaths, even those that appear to be completely unrelated 
to study drug (eg, a car accident in which a patient is a passenger).  
 Is life-threatening  – in the v iew of the investigator, the patient is at immediate risk of 
death at the time of the event.  This does not include an AE that had it occurred in a 
more severe form, might have caused death.  
 Requires in -patient hospi[INVESTIGATOR_801508] h ospi[INVESTIGATOR_059] .  In-
patient hospi[INVESTIGATOR_31561] a hospi[INVESTIGATOR_063] (any duration)  or an 
emergency room visit for longer than 24 hours.  Prolongation of existing hospi[INVESTIGATOR_24928] a hospi[INVESTIGATOR_801509], 
or is prolonged due to the development of a new AE as determined by [CONTACT_25043].  
 Results in persistent or significant disability/incapacity  (substantial disruption of 
one’s ability to conduct normal life functions).   
 Is a congenital anomaly/birth defect  
 Is an important medical event - Important medical events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_059], but may jeopardize the patient or 
may require intervention to prevent  one of the other serious outcomes listed above (eg, 
intensive treatment in an emergency room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug 
dependency or drug abuse).  
Criteria for Serious Sight -Threatening Ocular Adverse Events  
Criteria for serious sight -threatening ocular AEs include the following:  
 AE causes a decrease in VA to the level of light perception or worse.  
 AE requires surgical intervention (eg, vitreous tap or biopsy with IVT injection of anti -
infectives, laser or retinal cryopexy with gas) to prevent permanent loss of sight.  
 AE is associated with severe intraocular inflammation (ie, 4 + anterior chamber 
cell/flare or 4 + vitritis)  
 In the opi[INVESTIGATOR_871], AE may require medical intervention to prevent 
permanent loss of sight  
Criteria for reporting SAEs must be followed for these events.  
10.2.3.  Severity  
The severity of AEs will be graded according to the following scale:  
Mild:  Does not interfere in a  significant manner with the patient’s normal functioning level.  It 
may be an annoyance.  Prescription drugs are not ordinarily needed for relief of symptoms, but 
may be given because of personality of the patient.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 48 of 66 
CONFIDENTIAL  Moderate:   Produces some impairment of f unctioning but is not hazardous to health.  It is 
uncomfortable or an embarrassment.  Treatment for symptom may be needed.  
Severe:   Produces significant impairment of functioning or incapacitation and is a definite hazard 
to the patient’s health.  Treatmen t for the symptom may be given and/or the patient may be 
hospi[INVESTIGATOR_057].  
If a laboratory value is considered an AE, its severity should be based on the degree of 
physiological impairment the value indicates.  
10.2.4.  Causality  
The investigator must provide causality assessment as whether or not there is a reasonable 
possibility that the drug caused the adverse event, based on evidence or facts, his/her clinical 
judgment, and the following definitions.  The causality assessment must be made based on the 
available information and can be updated as new information becomes available.  
Include the following when applicable : 
The following factors should be considered when assessing causality:  
 Temporal relationship: time to onset vs time  drug was administered  
 Nature of the reactions: immediate vs. long term  
 Clinical and pathological features of the events  
 Existing information about the drug & same class of drugs  
 Concomitant medications  
 Underlying and concurrent illnesses  
 Response to d echallenge (drug discontinuation) or dose reduction  
 Response to rechallenge (re -introduction of the drug) or dose increase, when applicable  
 Patient’s medical and social history  
Causality to the study drug (including study drug administration):  
 Related:  
 The AE follows a reasonable temporal sequence from study drug administration, 
and cannot be reasonably explained by [CONTACT_25045], patient’s clinical 
(eg, disease under study, concurrent diseases, concomitant medications), or other 
external fa ctors.  
or 
 The AE follows a reasonable temporal sequence from study drug administration, 
and is a known reaction to the drug under study or its class of drugs, or is predicted 
by [CONTACT_25046].  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 49 of 66 
CONFIDENTIAL   Not Related:  
 The AE does not follow a reasonable sequence from study drug administration, or 
can be reasonably explained by [CONTACT_25045], patient’s clinical state 
(eg, disease under study, concurrent diseases, and concomitant medications) or 
other external factors.  
Causality to the study conduct (pr otocol specified procedure):  
 Related:  
 The AE follows a reasonable temporal sequence from a protocol specified 
procedure, and cannot be reasonably explained by [CONTACT_25045], 
patient’s clinical (eg, disease under study, concurrent diseases, con comitant 
medications), or other external factors.  
 Not Related:  
 The AE does not follow a reasonable sequence from a protocol specified procedure, 
or can be reasonably explained by [CONTACT_25045], patient’s clinical state 
(eg, disease under study , concurrent diseases, and concomitant medications) or 
other external factors.  
10.3. Safety Monitoring  
The investigator will monitor the safety of study patients at his/her site(s) as per the requirements 
of this protocol and consistent with current Good Clinical Practice (GCP).  Any questions or 
concerns should be discussed with the sponsor in a timely fashion.  The sponsor will monitor the 
safety data from across all study sites.  The Medical/Study Director will have primary 
responsibility for the emergi ng safety profile of the compound, but will be supported by [CONTACT_31599] (eg, Pharmacovigilance; Risk Management; Biostatistics and Data Management).  
Safety monitoring will be performed on an ongoing basis (eg, individual review of SAEs) and on 
a per iodic cumulative aggregate basis.  
10.4. Notifying Health Authorities, Institutional Review Board /Ethics 
Committee, and Investigators  
During the study, the sponsor and/or the CRO will inform health authorities, IECs/IRBs, and the 
participating investigators of a ny S[LOCATION_003]Rs (Suspected Unexpected Serious Adverse Reactions) 
occurring in other study centers or other studies of aflibercept, as appropriate per local reporting 
requirements. In addition, the sponsor and/or CRO will comply with any additional local safety 
reporting requirements.   
Upon receipt of the sponsor’s notification of a S[LOCATION_003]R that occurred with the study drug, the 
investigator will inform the Institutional Review Board (IRB)/Ethics Committee (EC) unless 
delegated to the sponsor.  
Event expectedness for  aflibercept is assessed against the Reference Safety Information for ROP  
in the current Investigator’s Brochure  that is effective for expedited safety reporting . 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106449] of the trial in the Clinical Study Report to health authorities and ECs/IRB as appropriate.  
11. STATISTICAL PLAN  
This section provides the basis for the sta tistical analysis plan (SAP) for the study.  The SAP will 
be finalized prior to the end of the study.  The final SAP will be issued before the database lock.  
11.1. Statistical Hypothesis  
This study will examine the following hypothesis for the primary efficacy v ariable regarding the 
proportion of patients with absence of active ROP and unfavorable structural outcomes at week  52 
of chronological age.  Statistical testing will be conducted to demonstrate the non -inferiority of 
the aflibercept group to the laser gro up, with a non -inferiority margin of 5% and a significance 
level of 5% (one -sided test).  
H0:  p t ≤ pc - 5% versus H 1:  p t ≥ p c - 5% 
where p t is the true proportion of patients with absence of active ROP and unfavorable structural 
outcomes at week  52 of chr onological age for the aflibercept group, and p c is the true proportion 
of patients with absence of active ROP and unfavorable structural outcomes at week  52 of 
chronological age for the laser group.  
The proposed non -inferiority margin of 5% is smaller tha n the smallest difference between laser 
and ranibizumab in RAINBOW  (a phase [ADDRESS_1106450] of IVT  ranibizumab  to laser 
in the management of ROP) , and not greater than the difference between the two ranibizumab 
doses.  
11.2. Justification of Sample S ize 
From the RAINBOW study, the response rate was 66.1% for the laser group and 88.1% for the 
0.2 mg ranibizumab group in zone II disease. Furthermore, based on the clinical evidence for the 
aflibercept investigator -initiate d studies  (Salman, 2015 ) (Huang, 2018 ) (Sukgen, 2018 ) 
(Sidorenko, publication in progress ), the response rates range all the way up to 100% (with at least 
2 studies demonstrating a 100% response rate in terms of favorable anatomic structural 
outcomes/prevention of unfavorable anatomic structu ral outcomes) with IVT aflibercept dose s 
ranging from  0.4 mg to 1 mg.  An estimated 90% response rate for the aflibercept group and 66.1% 
response rate for the laser group would be a safe assumption.  It is assumed that the proportion of 
patients with abse nce of active ROP will be in line with this.  
A sample size of 84  patients in the aflibercept group and 28 patients in the laser group (randomized 
in a 3:1 ratio) will provide 92% power for rejecting the null hypothesis at a 1-sided 5%  significance 
level.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 51 of 66 
CONFIDENTIAL  11.3. Analysis Sets  
11.3.1.  Full Analysis Set  
The full analysis set (FAS) will include all randomized patients who received any study treatment.  
The analysis on the FAS will be performed according to the treatment assigned at baseline (as 
randomized).  
11.3.2.  Per Protocol Set  
The per protocol set ( PPS) includes all patients in the FAS who had no important protocol 
deviations.   Final determinations of the PPS will be made before database lock.  Analysis of the 
PPS will be performed according to the treatment actual ly received (a s treated).  The PPS will be 
used for sensitivity analysis of the primary endpoint.  
11.3.3.  Safety Analysis Set  
The safety analysis set (SAF) includes all randomized patients  who received any study treatment 
(active or laser); it is based on the treatment actually received (as treated).  Treatment 
compliance/administration and all clinical safety variables will be analyzed using the SAF.  
11.3.4.  Pharmacokinetic Analysis Set  
The PK analysis population includes all patients who received any study drug and who had a at 
least [ADDRESS_1106451] dose of study drug.  
11.4. Statistical Methods  
Unless stated otherwise, all variables will be analyzed descriptively with appropriate statistical 
methods:  continuous variables by [CONTACT_358049] (ie, m ean, standard deviation, median, 
quartiles, minimum, and maximum), and categorical variables by [CONTACT_22977].  
All statistical analyses will be performed using Statistical Analysis System (SAS); the version used 
will be specified in the SAP.  
11.4.1.  Patient Disposition  
The following will be provided:  
 The total number of screened patients:  met the inclusion criteria regarding the target 
indication and signed the ICF  
 The total number of randomized patients:  received a randomization number  
 The total nu mber of patients who discontinued the study, and the reasons for 
discontinuation  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 52 of 66 
CONFIDENTIAL   The total number of patients who discontinued from study treatment, and the reasons 
for discontinuation  
 A listing of patients treated but not randomized, patients randomized b ut not treated, 
and patients randomized but not treated as randomized  
 A listing of patients prematurely discontinued from treatment, along with reasons for 
discontinuation  
11.4.2.  Demography and Baseline Characteristics  
Demographic and baseline characteristics wil l be summarized descriptively by [CONTACT_1570], 
and by [CONTACT_25048].  
11.4.3.  Efficacy Analyses  
[IP_ADDRESS].  Primary Efficacy Analysis  
The primary efficacy variable analysis will be conducted on the FAS.  The primary analysis is a 
statistical evaluation of non -inferi ority of aflibercept vs. laser at week [ADDRESS_1106452] to the primary efficacy variable  (the proportion of patients with absence of active 
ROP and of unfavorable structural outcomes) .  The non -inferiority margin is set at 5%.   Superio rity 
testing will follow if non -inferiority is established.   Sensitivity analysis of the primary endpoint 
will also be conducted based on the PPS. 
If data are available from the week [ADDRESS_1106453] (LOCF) 
to the E OS visit for analysis.  If the patient discontinued at or before this visit, no data will be 
carried forward and the patient will be considered a non -responder.  For patients with both eyes 
enrolled in the study, both eyes must meet the endpoint.  Patients  with only one study eye enrolled 
will be responders if the respective eye responds.  
The statistical analysis will be performed using the Cochran -Mantel -Haenszel method stratified 
by [CONTACT_801512] .  The 1-sided 95% Mantel -Haenszel confidence interval  using normal 
approximation of the difference of response rates between the aflibercept group and the laser group 
will be calculated.  Aflibercept will be considered to be non -inferior to laser if the confidence 
interval of the difference lies entirely abo ve -5%. 
Furthermore, eyes will be considered to be non -responders if rescue treatment is given.   The 
primary analysis for this endpoint will be based on the investigator assessment of, and sensitivity 
analyses based on the central RC data will be conducted . 
[IP_ADDRESS].  Secondary and Exploratory Efficacy Analyse s 
The efficacy variables will be analyzed using the same method as for the analysis of the primary 
efficacy variable.  
11.4.4.  Control of Multiplicity  
If the primary endpoint is declared significant, a hierarchical testing procedure will be used for the 
analysis of the secondary endpoints to control the overall alpha error rate at the 0.05 level.  The 
order of the endpoints for hierarchical testing will be specified in the SAP.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 53 of 66 
CONFIDENTIAL  11.4.5.  Safety Analysis  
Safety variables will b e summarized on the SAF through week 52 of chronological age for both 
treatment groups.  
[IP_ADDRESS].  Adverse Events  
Definitions  
For safety variables, 3 observation periods are defined:  
 The pretreatment period is defined as the time from signing the ICF to before the fi rst 
dose of study drug.  
 The treatment period is defined as the day from first dose of study drug to the last dose 
of study drug.  
 The post -treatment period is defined as the time af ter the last dose of study drug.  
A TEAE is defined as an event (or an exacer bation of a preexisting event during the treatment 
period) that is observed or reported after the first administration of study drug, and no later than 
[ADDRESS_1106454] administration of study drug.  
Analysis  
All AEs reported in this study will be coded using the currently available version of the Medical 
Dictionary for Regulatory Activities (MedDRA®).  Coding will be to lowest level terms.  The 
verbatim text, the preferred term (PT), and the primary system organ class (SOC) will be listed.  
Summaries of a ll TEAEs by [CONTACT_1570], and by [CONTACT_801533], ocular fellow eye, and 
non-ocular TEAEs, will include:  
 The number (n) and percentage (%) of patients  with at least 1 TEAE by [CONTACT_3592]  
 TEAEs by [CONTACT_926] (according to the grading scale outlined in Section 10.2.3 ), 
presented by [CONTACT_3592]  
 TEAEs by [CONTACT_801534] (related, not related), presented 
by [CONTACT_801535] d other SAEs will be listed and summarized by [CONTACT_1570].  
Treatment -emergent adverse events leading to permanent treatment discontinuation will be listed 
and summarized by [CONTACT_1570].  
[IP_ADDRESS].  Ocular Safety  
Ocular safety variables (eg, IOP measurements) w ill be analyzed descriptively at their scheduled 
visit, including changes from baseline.  All ocular safety parameters will be summarized using 
descriptive statistics.  Information from fundus photography and FA (including the substudy) may 
also be used to  assess ocular safety.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 54 of 66 
CONFIDENTIAL  [IP_ADDRESS].  Other Safety  
Vital Signs  
Vital signs (temperature, pulse, blood pressure, and respi[INVESTIGATOR_1487]) will be summarized by 
[CONTACT_109994].  
Laboratory Tests  
Laboratory test results will be summarized by [CONTACT_25052].  
Number and percentage of patients with a potentially clinically significant value (PCSV) at any 
post-randomizatio n time point will be summarized for each clinical laboratory test for all patients 
and separately for patients in whom the PCSV criterion was normal or missing at baseline.  
Shift tables based on baseline normal/abnormal and other tabular and graphical met hods may be 
used to present the results for laboratory tests of interest.  
Listings will be provided with flags indicating the out of laboratory range values.  
[IP_ADDRESS].  Treatment Exposure  
Exposure to study drug will be examined for each patient.  The total number of treatments 
administered to each patient and the duration of treatment will be analyzed and summarized using 
descriptive statistics by [CONTACT_801536]  
[IP_ADDRESS].  Treatment Compliance  
Compliance with protocol defined study medication will  be calculated as follows:  
Treatment compliance = (number of received injections through a given week)/(number of planned 
injections during the period of participation in the study through the given week) x 100%.  
11.4.6.  Pharmacokinetics  
[IP_ADDRESS].  Analysis of Drug Concentra tion Data  
The plasma concentrations of free and bound aflibercept over time will be summarized by 
[CONTACT_9086].  
No formal statistical hypothesis testing will be performed.  
[IP_ADDRESS].  Pharmacokinetics and Pharmacokinetics/Pharmacodynamics Analyses  
Populatio n PK and exposure -response analyses for blood pressure may be performed, as 
appropriate, and presented in separate reports.  
11.4.7.  Analysis of Immunogenicity Data  
Anti-drug antibody status (negative or positive) and titer over the study duration may be classified  
as follows:  
 Treatment -emergent ADA response, defined as any post -dose positive ADA assay 
response when the baseline results are negative  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 55 of 66 
CONFIDENTIAL   Treatment -boosted ADA response, defined as any post -dose positive ADA assay 
response that is 4 -fold over baseline tit er levels when baseline is positive in the ADA 
assay  
 Maximum ADA titer values  
 Low (titer <1,000)  
 Moderate (1,000≤ titer ≤10,000)  
 High (titer >10,000)  
 NAb status (positive or negative) for samples that are positive in the ADA assay  
Listings of ADA positivity and titers presented by [CONTACT_4676], time point, and study treatment received 
will be provided.  Incidence  of treatment -emergent and treatment -boosted ADA will be assessed 
as absolute occurrence (N) and percent of patients (%), group ed by [CONTACT_101850].  
The influence of ADAs on individual PK profiles will be evaluated.  Assessment of impact of 
ADA on safety and efficacy may be provided.  
11.4.8.  Analysis of Biomarker Data  
Biomarker exploratory analyses will be described in the SAP.  
11.5. Interim Analysis  
No interim analysis is planned.  
11.6. Additional Statistical Data Handling Conventions  
The following analysis and data conventions will be followed:  
Definition of baseline:  
 The baseline assessment is defined as the latest valid pre -dose assessme nt 
General rules for handling missing data:  
 Rules for handling missing data for efficacy assessments are described in the efficacy 
analysis section .  Additional details will be provided in the SAP.  
 AE variables  
For some AEs it is important to determine whe ther the AE started before or after the 
first active aflibercept injection. If the AE start date is partially missing, it will be 
imputed by [CONTACT_801537] (considering other available data, e.g., stop date) to 
be conservative.  
 Prior/concomitant medication  
For the tabulation of prior and concomitant medication, partially missing start dates of 
the medication will be imputed by [CONTACT_801538], partially missing 
stop dates will be imputed by [CONTACT_801539]-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 56 of 66 
CONFIDENTIAL   No imputa tions for missing laboratory data, vital sign data, or physical examination 
data will be made.  
Unscheduled assessments  
 Assessments taken outside of protocol allowable windows will be  displayed according 
to the CRF assessment recorded by [CONTACT_093].   Unscheduled assessments will not 
be included in the summaries . 
11.7. Statistical Considerations Surrounding the Premature Termination 
of a Study  
If the study is terminated prematurely, only those parameters required for the development 
program and/or reporting to regulatory authorities will be summarized.  Investigator and sponsor 
responsibilities surrounding the premature termination of a study are presented in Section  15.1. 
12. QUALITY CONTROL AND QUALITY ASSURANCE  
In accordance with ICH E6, the sponsor is responsible for quality assurance to ensure that the 
study is conducted and the data generated, recorded, and reported in compliance with the protocol, 
GCP,  and any applicable regulatory requirement(s).  The planned quality assurance and quality 
control procedures for the study are described in this section.  
12.1. Data Management and Electronic Systems  
12.1.1.  Data Management  
A data management plan specifying all relevant aspects of data processing for the study (including 
data validation [quality -checking], cleaning, correcting, releasing) will be maintained and stored 
at Regeneron (Sponsor).  
A medical coding plan will specify the processes and the dictionary used for codi ng.  All data 
coding (eg, AEs, baseline findings, medication, medical history/surgical history/ophthalmic 
history) will be done using internationally recognized and accepted dictionaries.  
The CRF data for this study will be collected with an electronic dat a capture (EDC) system.  
12.1.2.  Electronic Systems  
Electronic systems that may be used to process and/or collect data in this study will include the 
following:  
 IVRS/IWRS system – randomization, study drug supply  
 EDC system – data capture  – Medidata Rave  
 Statistica l Analysis System (SAS) – statistical review and analysis  
 Pharmacovigilance safety database  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 57 of 66 
CONFIDENTIAL  12.2. Study Monitoring  
12.2.1.  Monitoring of Study Sites  
The study monitor and/or designee (eg, contract research organization [CRO] monitor) will visit 
each site prior to enroll ment of the first patient, and periodically during the study.  This study will 
use the principles of risk -based monitoring (ICH).  This means that the number of visits for any 
given site may vary based on site risk indicators.  The investigator must allow study -related 
monitoring.  
The study monitors will perform ongoing source data review to verify that data recorded in the 
CRF by [CONTACT_1191], complete, and verifiable from source documents, 
that the safety and rights of patients a re being protected, and that the study is being conducted in 
accordance with the current approved protocol version and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
12.2.2.  Source Document Requirements  
Investigators are required to prepare and maintain adequate and accurate patient records (source 
documents).  The site is responsible to ensure quality within their records and systems and are 
accountable for ensuring that all source data and CRF data are timely, accurate and comple te. 
The investigator must keep all source documents on file with the CRF (throughout this protocol, 
CRF refers to either a paper CRF or an electronic CRF).  Case report forms and source documents 
must be available at all times for inspection by [CONTACT_25060].  
12.2.3.  Case Report Form Requirements  
Study data obtained in the course of the clinical study will be recorded on electronic Case Report 
Forms (CRFs) within the EDC system by [CONTACT_1146].  All required CRFs must be 
completed for each and every patient enrolled in the study.  The investigator must ensure the 
accuracy, completeness, and timeliness of the data reported to the sponsor in the CRFs.  After 
review of the clinical data for each pati ent, the investigator must provide an electronic signature.  
A copy of each patient CRF casebook is to be retained by [CONTACT_801540] r 
and regulatory authorities.  
Corrections to the CRF  will be entered in the CRF by [CONTACT_31612].  
All changes, including date and person performing corrections, will be available via the audit trail, 
which is part of the EDC s ystem.  For corrections made via data queries, a reason for any alteration 
must be provided.  
12.3. Audits and Inspections  
This study may be subject to a quality assurance audit or inspection by [CONTACT_25063].  Should this occur, the inves tigator is responsible for:  
 Informing the sponsor of a planned inspection by [CONTACT_50482], and authorizing the sponsor’s participation in the inspection  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 58 of 66 
CONFIDENTIAL   Providing access to all necessary facilities, study data, and do cuments for the inspection 
or audit  
 Communicating any information arising from inspection by [CONTACT_31614]  
 Taking all appropriate measures requested by [CONTACT_801541], CRFs, 
medical records, correspondence, ICFs, IRB/EC files, documentation of certification and quality 
control of supporting laboratories, and records rel evant to the study maintained in any supporting 
pharmacy facilities.  Conditions of study material storage are also subject to inspection.  In 
addition, representatives of the sponsor may observe the conduct of any aspect of the clinical study 
or its suppo rting activities both within and outside of the investigator's institution.  
In all instances, the confidentiality of the data must be respected.  
12.4. Study Documentation  
12.4.1.  Certification of Accuracy of Data  
A declaration assuring the accuracy and content of the da ta recorded on the CRF/eCRF must be 
signed electronically by [CONTACT_093].  This signed declaration accompanies each set of patient 
final CRF s/eCRF s that will be provided to the sponsor.  
12.4.2.  Retention of Records  
The investigator must retain all essential s tudy documents, including ICFs, source documents, 
investigator copi[INVESTIGATOR_3110], and drug accountability records for at least [ADDRESS_1106455] be destroyed in a manner tha t ensures 
confidentiality.  
If the investigator's personal situation is such that archiving can no longer be ensured, the 
investigator must inform the sponsor (written notification) and the relevant records will be 
transferred to a mutually agreed -upon dest ination.  
13. ETHICAL AND REGULATO RY CONSIDERATIONS  
13.1. Good Clinical Practice Statement  
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study 
will be conducted in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory 
requirements.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106456] be reviewed and approved by [CONTACT_104264]/EC.  A copy of the IRB/EC -approved ICF and documentation 
of approval must be provided to the sponsor before study drug will be shipped to  the study site.  
It is the responsibility of the investigator or designee (if acceptable by [CONTACT_427]) to obtain 
written informed consent from each patient's parent(s) or legal guardian(s) prior to the patient’s 
participation in the study and after  the aims, methods, objectives, and potential hazards of the study 
have been explained to the fullest possible extent in language that the patient's parent(s) or legal 
guardian(s) can understand.  The ICF should be signed and dated by [CONTACT_102]’s parent( s) or legal 
guardian(s) and the same investigator or designee who explained the ICF.  
Local law must be observed in deciding whether 1 or both parents/guardians consent is required.  
If the patient’s parent(s) or legal guardian(s) can write but cannot read, the ICF will be read to 
them before signing their name [CONTACT_106253].  If the patient’s parent(s) or legal guardian(s) can 
understand but can neither write nor read, the ICF will be read to them in the presence of an 
impartial witness, who will sign and date the ICF to confirm that informed consent was given.  
If only [ADDRESS_1106457] document the reason the 
other parent or guardian did not sign.  The patient's parent/legal guardian may also be required to 
sign and date the ICF, as determined by [CONTACT_1201]/EC and in accordance with the local regulations 
and requirements.  
 Patient's parent(s)/legal guardian(s) who can write but cannot read will have the assent 
form read to them before writing their name [CONTACT_25084].  
 Patient's parent(s)/legal guardian(s) who can understand but who can neither write nor 
read will have the ICF read to them in presence of an impartial witness, who will sign 
and date the ICF to confirm that informed consent was given.  
The original ICF must be retained by [CONTACT_31616]’s study record, and a 
copy of the signed ICF must be given to the patient’s parent(s) or legal guardian(s).  
If new safety information results in significant changes in the risk/benefit assessment, or i f there 
are significant changes to the study procedures, the ICF must be reviewed and updated 
appropriately.  All study patients ’ parent(s) or legal guardian(s) must be informed of the new 
information and provide their written consent if they wish the pati ent to continue in the study.  The 
original signed revised ICF must be maintained in the patient’s study record and a copy must be 
given to the patient’s parent(s) or legal guardian(s).  
13.3. Patients’ Confidentiality and Data Protection  
The investigator must ta ke all appropriate measures to ensure that the anonymity of each study 
patient will be maintained.  Patients should be identified by a patient identification number and 
date of birth , on CRFs or other documents submitted to the sponsor. Documents that will  not be 
submitted to the sponsor (eg, signed ICF) must be kept in strict confidence.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 60 of 66 
CONFIDENTIAL  The patient’s and investigator's personal data, which may be included in the sponsor database, will 
be treated in compliance with all applicable laws and regulations.  The  sponsor shall take all 
appropriate measures to safeguard and prevent access to this data by [CONTACT_13159].  
13.4. Institutional Review Board/Ethics Committee  
An appropriately constituted IRB/EC, as described in ICH guidelines for GCP, must review and 
approve:  
 The protocol, ICF, and any other materials to be provided to the patient's parent(s)/legal 
guardian(s) (eg,  advertising) before any patient may be enrolled in the study  
 Any amendment or modification to the study protocol or ICF before implemen tation, 
unless the change is necessary to eliminate an immediate hazard to the patient, in which 
case the IRB/EC should be informed as soon as possible  
 Ongoing studies on an annual basis or at intervals appropriate to the degree of risk  
In addition, the I RB/EC should be informed of any event likely to affect the safety of patients or 
the continued conduct of the clinical study.  
A copy of the IRB/EC approval letter with a current list of the IRB/EC members and their functions 
must be received by [CONTACT_801542].  The 
approval letter should include the study number and title, the documents reviewed, and the date of 
the review.  
Records of the IRB/EC review and approval of all study documents (including approva l of ongoing 
studies) must be kept on file by [CONTACT_093].  
13.5. Clinical Study Data Transparency  
Final study results will be published on a public clinical trial website according to applicable local 
guidelines and regulations.  Treatment codes will be dis seminated to each investigation site 
thereafter.  
14. PROTOCOL AMENDMENTS  
The sponsor may not implement a change in the design of the protocol or ICF without an IRB/EC -
approved amendment.  Where required per local legislation, regulatory authority approval will  also 
be sought.  
15. PREMATURE TERMINATIO N OF THE STUDY OR CL OSEOUT 
OF A SITE  
15.1. Premature Termination of the Study  
The sponsor has the right to terminate the study prematurely.  Reasons may include efficacy, 
safety, or futility, among others.  Should the sponsor  decide to terminate the study, the 
investigator(s) will be notified in writing.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:[ADDRESS_1106458] the right to closeout a site prematurely.  
Investigator’s Decision  
The investigator must notify the sponsor of a desire  to closeout a site in writing, providing at least 
30 days’ notice.  The final decision should be made through mutual agreement with the sponsor.  
Both parties will arrange the closeout procedures after review and consultation.  
Sponsor’s Decision  
The spons or will notify the investigator(s) of a decision to closeout a study site in writing.  Reasons 
may inclu de the following, among others:  
 The investigator has received all items and information necessary to perform the study, 
but has not enrolled any patient  within a reasonable period of time  
 The investigator has violated any fundamental obligation in the study agreement, 
including but not limited to, breach of this protocol (and any applicable amendments), 
breach of the applicable laws and regulations, or br each of any applicable ICH 
guidelines  
 The total number of patients required for the study are enrolled earlier than expected  
In all cases, the appropriate IRB/EC and Health Authorities must be informed according to 
applicable regulatory requirements, and adequate consideration must be given to the protection of 
the patients’ interests.  
16. CONFIDENTIALITY  
Confidentiality of information is provided as a separate agreement.  
17. FINANCING AND INSURA NCE  
Financing and insurance information is provided as a separate agr eement.  
18. PUBLICATION POLICY  
Publication rights and procedures will be outlined in a separate clinical study agreement.  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 62 of 66 
CONFIDENTIAL  19. REFERENCES  
Blencowe H, Lee AC, Cousens S, et al.  Preterm birth -associated neurodevelopmental impairment 
estimates at regional and global  levels for 2010.   Pediatr Res 2013;[ADDRESS_1106459] 1:17 -34. 
Gilbert C, Rahi J, Eckstein M, et al.  Retinopathy of prematurity in middle -income countries.   The 
Lancet 1997;350(9070):12 -14. 
Harder BC, Schlichtenbrede FC, Von Baltz S, et al.  Intravitreal bevacizumab for retinopathy of 
prematurity: refractive error results.  Am J Ophthalmol 2013 Jun;155(6):[ADDRESS_1106460] therapy for retinopathy of 
prematurity.   Clin Perinatol 2014;41:[ADDRESS_1106461];55(10):6194 -6203.  
Hellström A  and Smith LEH . Dammann O.  Retinopathy of prematuri ty. Lancet 
2013;382(9902):1445 -1457.  
Huang CY, Lien R, Wang NK, et al.  Changes in systemic vascular endothelial growth factor levels 
after intravitreal injection of aflibercept in infants with retinopathy of prematurity.   Graefes Arch 
Clin Exp Ophthalmol  2018;256, 479 -487.  
Hwang CK, Baker HG, Hutchinson AK, et al.  Outcomes after intravitreal bevacizumab versus 
laser photocoagulation for retinopathy of prematurity: a 5 -year retrospective analysis.  
Ophthalmology 2015 May;122(5):1008 -1015.  
Mintz -Hittner HA , Kennedy KA, and Chuang AZ.  Efficacy of intravitreal bevacizumab for stage 
3+ retinopathy of prematurity.  NEJM  2011;364(7):603 -15.  
Mutlu FM  and Sarici SU.  Treatment of retinopathy of prematurity: a review of conventional and 
promising new therapeutic options.   Int J Ophthalmol 2013;6:228 -236. 
Painter SL, Wilkinson AR, Desai P, et al.  Incidence and treatment of retinopathy of prematurity 
in England between 1990 and 2011: database study. Br J of Ophth 2015;99(6):807.  
Pertl L, Steinwender G, Mayer C, et al.  A Systematic Review and Meta -Analysis on the Safety of 
Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of 
Prematurity.   PLoS One. 2015;10:e0129383.  
Salman AG  and Said AM.   Structural, visual and refractive outcome s of intravitreal aflibercept 
injection in high -risk prethreshold type 1 retinopathy of prematurity.  Ophth Res 2015;53:15 -20. 
Sidorenko EE.  Treatment of retinopathy of prematurity with aflibercept in Russia.  Presented at: 
17th International Conference o n Clinical and Experimental Ophthalmology.  [ADDRESS_1106462] 01 -03. 
Moscow, Russia. Available from:  https://ophthalmology.conferenceseries.com/ 
abstract/2018/treatment -of-retinopathy -of-prematurity -with-aflibercept -in-russia  
Sidorenko Pulication in progress, Azu ma Oral Communication  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 63 of 66 
CONFIDENTIAL  Stone J, Chan -Ling T, Pe'er J, et al.  Roles of Vascular Endothelial Growth Factor and Astrocyte 
Degeneration in the Genesis of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci 
1996;37:290 -99. 
Sukgen EA  and Kocluk Y.  Comparison of clinical outcomes of intravitreal ranibizumab and 
aflibercept treatment for retinopathy of prematurity.  Graefe’s Archive for Clinical and 
Experimental Ophthalmology.  Revised 2018 Apr 16.  Available from: 
https://doi.org/10.1007/s00417 -018-4168 -5. 
Youn g TL, Anthony DC, Pi[INVESTIGATOR_835] E, et al . Foley E, Smith LE.  Histopathology and vascular 
endothelial growth factor in untreated and diode laser -treated retinopathy of prematurity.  J 
AAPOS. 1997;1:105 -10. 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 64 of 66 
CONFIDENTIAL  20. INVESTIGATOR’S AGREE MENT  
I have read the attached protocol:  Randomized, Controlled , Multi -Center Study to Assess the 
Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation 
in Patients with Retinopathy of Prematurity, and agree to abide b y all provisions set forth therein.  
I agree to comply with the current International Council for Harmonisation Guideline for Good 
Clinical Practice and the laws, rules, regulations, and guidelines of the community, country, state, 
or locality relating to t he conduct of the clinical study.  
I also agree that persons debarred from conducting or working on clinical studies by [CONTACT_50487] a partnership 
in which the sponsor is  involved.  I will immediately disclose it in writing to the sponsor if any 
person who is involved in the study is debarred, or if any proceeding for debarment is pending, or, 
to the best of my knowledge, threatened.  
This document contains confidential inf ormation of the sponsor, which must not be disclosed to 
anyone other than the recipi[INVESTIGATOR_14251]/EC.  I agree to ensure that this 
information will not be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of the sponsor.  
 
 
 
   
(Signature [CONTACT_7919])   (Date)  
   
(Printed Name)    
 
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 65 of 66 
CONFIDENTIAL  APPENDIX  1. FLUORESCEIN ANGIOGRA PHY SUB -STUDY  
Fluorescein Angiography Sub -Study  
This is an exploratory analysis for fluorescein angiography (FA) conducted as a sub -study to 
protocol VGFTe -ROP -1920.  Investigational sites that are participating in VGFTe -ROP -[ADDRESS_1106463] the abilit y and prior experience to perform FAs on the patient/study population identified as 
part of VGFTe -ROP -1920.  These specifically include experience in performing FA in pre -term 
infants using a digital fiber optic contact [CONTACT_801543] l growth 
factor inhibitors for retinopathy of prematurity.  
A. Sub-study Objective  
The objective of this sub -study is to explore the use of FA to assess vascular leakage, non -
perfusion, ischemia and the development of the normal retinal vasculature in the population under 
study pre - and post -treatment.  It will involve the injection/administration of intravenous/oral 
fluorescein dye into the patient, followed by [CONTACT_801544] -angle photographs and angiographic 
images of the retina in both e yes.  As FA has the ability to image vessels and leakage accurately, 
it may provide additional information related to treatment response and on the disease state beyond 
that achievable with Color Fundus Photography Imaging.  This will also help us generate  a Non -
Perfusion Index (NPI).  The NPI [INVESTIGATOR_801510] -perfused (i.e. ischemic) retina to perfused retina 
as seen on FA.  
B. Number of Patients and Sites  
Patients will be enrolled at the investigator’s discretion at sites that have access to FA imaging.   
There will be no cap on the number of patients or sites that may participate.  
C. Timing of Fluorescein Angiography  
FA will be performed prior to administration of very first study treatment (optional yet desired to 
compare NPI [CONTACT_48599]) and at the week 52  of chronological age visit (mandatory)  (Table  1).  
Additional FA may be performed at the investigator’s discretion in conjunction with all the other 
scheduled study visits for the main study, as well as at any other treatment intervention.  
Detailed instructions for procedure, image collection and transmission will be provided in the 
study procedure manual.  
 
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Clinical Study Protocol   VGFTe -ROP -1920  Amendment 1  
 
 
Regeneron Pharmaceuticals, Inc.   Page 66 of 66 
CONFIDENTIAL  SIGNATURE [CONTACT_11715] ’S RESPONSIBLE OFFIC ERS  
(Medical/Study Director, Regulatory Representative, Clinical Study Lead, and 
Biostatistician)  
To the best of my knowledge, this report accurately describes the planned conduct of the study.  
Study Title:   Randomized, Controlled , Multi -Center  Study to Assess the Efficacy, Safety, and 
Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with 
Retinopathy of Prematurity  
Protocol Number:  VGFTe -ROP -1920  
Protocol Version:  VGFTe -ROP -1920  Amendment 1  
 
See appended el ectronic signature [CONTACT_25085]’s Responsible Medical/Study Director  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Regulatory Liaison  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Clinical Study Lead  
 
 
See appended electronic signature [CONTACT_25085]’s Responsible Biostatistician  
                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
Signature [CONTACT_11032]-RIM-00083535 v1.0
Signature [CONTACT_11032]-RIM-00083535 v1.0 ApprovedESig Approval
00
ESig Approval
2019 21:04:37 GMT[PHONE_006]
ESig Approval
2019 21:13:21 GMT[PHONE_006]
ESig Approval
9 22:30:51 GMT[PHONE_006]                                        VV-RIM-00083535-1.0 Approved - 29 Jul 2019 GMT-5:00
